Am J Clin Oncol (CCT) 19(6): 639–647, 1996

© 1996 Lippincott–Raven Publishers, Philadelphia

AUTHOR INDEX

Abadir, Rushdy
—Demmy, Todd L.: Lung carcinoma-M_0 Patterns and results of radiotherapy of all patients referred to one department, 512
Abcar, Antoine. See Brodsky, Jeffrey
Abitbol, Andre A.
—Wolfson, Aaron H.; Lewin, Alan A.; Houdek, Pavel V.; Laufer, Karen A.; Brandon, Alfred H.; Ting, Joseph Y.; Raub, William A. Jr; Averette, Hervy E.; Sevin, Bernd-U.; Markoe, Arnold M.: Management of stage I-B, II-A, and II-B carcinoma of cervix with high-dose-rate brachytherapy: Initial results of institutional clinical trial, 223
Acito, L. See Di Costanzo, F.
Adjahoto, Etsé Outcha. See Delaloye, Jean-Francois
Aeppli, Dorothee M. See Lee, Chung K.
Alba, Emilio
—Sánchez-Chaparro, Miguel Angel; Alonso, Lorenzo; Ribelles, Nuria; Delgado, Juan Ramon; Rueda, Antonio; Tenllado, Pedro Pable; Solano,Jose; Urquiza, Rafael: Cisplatin, 5-fluorouracil, and high-dose folinic acid in patients with advanced unresectable head and neck cancer, 140
Albanell, J. See Bellmunt, J.
Alberts, David S. See Yeilding, Allen
Alonso, Lorenzo. See Alba, Emilio
Altomonte, Maresa. See Merimsky, Ofer
Amann, Stephen T. See Cockey, George H.
Amato, S. See Vallejo, C.
Amir, Gail. See Ron, Ilan G.
Ampil, Federico L.
—Nanda, Anil; Willis, Brian K.; Nandy, Indrani; Meehan, Rosemary: Metastatic disease in the cerebellum. The LSU experience in 1981-1993, 509
Anastasi, P. See Colozza, M.
Anderson, Clay M.
—Walters, Ronald S.; Hortobagyi, Gabriel N.: Mediastinitis related to probable central vinblastine extravasation in a woman undergoing adjuvant chemotherapy for early breast cancer, 566
Anderson, Lisa. See Corn, Benjamin W.
Ando, Masahiko. See Ando, Yuichi
Ando, Yuichi
—Sugiura, Seiji; Ando, Masahiko; Minami, Hironobu; Nomura, Fumio; Sakai, Shuzo; Shimokata, Kaoru: Acceptability of patients with brain metastases for clinical trials of chemotherapy for metastatic non-small-cell lung cancer, 478
Angiona, S. See Di Costanzo, F.
Anscher, Mitchell S. See Hebert, Mary E.
Antognoli, Stefania. See Giorgi, Francesca
Antoniou, F. See Pectasides, D.
Aral, Isamettin. See Aziz, Hassan
Arepally, Gowthami
—Kenyon, Lawrence C.; Lavi, Ehud: Late onset of isolated central nervous system metastasis of liposarcoma. A case report, 351
Aristei, C.
See Colozza, M.
See Maranzano, Ernesto
Armand, Jean Pierre. See Bensmaine, Mohamed-El-Amine
Armenakas, Noel A. See Miller, Lawrence S.
Armstead, Barbara. See Vaughn, David J.
Arroyo, A. See Leone, B.
Asbell, Sucha O. See Simpson, Joseph R.
Asbury, Robert
—Blessing, John A.; Moore, David: Phase II trial of aminothiadiazole in patients with mixed mesodermal tumors of the uterine corpus: A Gynecologic Oncology Group study, 400
Astrahan, Melvin A. See Petrovich, Zbigniew
Atahan, I. Lale. See Barişta, Ibrahim
Athanassiou, A. See Pectasides, D.
Atkins, James N.
—Muss, Hyman B.; Case, L. Douglas; Richards, Frederick II; Grote, Thomas; McFarland, James: Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association, 23
Attivissimo, Lori A.
—Fetten, James V.; Kreis, Willi: Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer, 581
Averette, Hervy E. See Abitbol, Andre A.
Aziz, Hassan
—Hussain, Fazal; Edelman, Scott; Cirrone, Joseph; Aral, Isamettin; Fruchter, Rachel; Homel, Peter; Rotman, Marvin: Age and race as prognostic factors in endometrial carcinoma, 595
Azli, Nacer. See Bensmaine, Mohamed-El-Amine

Bafaloukos, D.
—Pavlidis, N.; Fountzilas, G.; Skarlos, D.; Klouvas, G.; Makrantonakis, P.; Giannakakis, T.; Tsavaris, N.; Kosmidis, P.: Recombinant interferon ALFA-2A in combination with carboplatin, vinblastine, and bleomycin in the treatment of advanced malignant melanoma, 296
See Pectasides, D.
Baharav, Ehud. See Merimsky, Ofer
Ball, Edward D. See deMagalhaes-Silverman, Margarida
Baltali, Eşmen. See Barişta, Ibrahim
Banus, J.M. See Bellmunt, J.
Barbieri, M. See Vallejo, C.
Barişta, Ibrahim
—Baltali, Eşmen; Güllü, Ibrahim H.; Güler, Nilüfer; Çelik, Ismail; Saraçbaşi, Osman; Tekuzman, Gülten; Kars, Ayşe; Ozişik, Yavuz; Ruacan, Sevket; Atahan, I. Lale; Firat, Dinçer: Factors influencing the distribution of metastases and survival in metastatic breast carcinoma, 569
Bartoli, C. See Zambetti, M.
Bauer, Jean See Delaloye, Jean-Francois
Beck, Jörn D. See Grabenbauer, Gerhard G.
Bella, M. See Di Costanzo, F.
Bellissant, Eric
—Bénichou, Jacques; Chastang, Claude: The group sequential triangular test for phase II cancer clinical trials, 422
Bellmunt, J.
Ribas, A.; Albanell, J.; Bermejo, B.; Vera, R.; De Torres, J.A.; Morote, J.; Lopez-Pacios, M.A.; Banus, J.M.; Rovirosa, A.; Carulla, J.; Sole, L.A.: M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcioma of the bladder, 344
Benammar, Alia. See Haghbin, Mahroo
Bender, Hans. See Emrich, Jacqueline G.
Beneventi, Sara. See Maranzano, Ernesto
Bengala, Carmelo. See Michelotti, Andrea
Bénichou, Jacques. See Bellissant, Eric
Benner, Steven E. See Huber, Martin H.
Bensmaine, Mohamed-El-Amine
—Azli, Nacer; Domenge, Christian; Armand, Jean Pierre; Cvitkovic, Esteban: Phase I-II trial of recombinant interferon alpha-2b with cisplatin and 5-fluorouracil in recurrent and/or metastatic carcinoma of head and neck, 249
—Guillot, Thierry; Bernal, Edouardo Tellez; Janot, Francois; Sigal, Robert; Domenge, Christian; Wibault, Pierre; Armand, Jean-Pierre; Cvitkovic, Esteban: Neoadjuvant chemotherapy with cisplatin-vindesine-5-fluorouracil and folinic acid for locally advanced head and neck carcinoma, 356
Benson, Al B. See Sparano, Joseph A.

Bermejo, B. See Bellmunt, J.
Bernal, Edouardo Tellez See Bensmaine, Mohamed-El-Amine
Berrocal, A. See Feliu, J.
Berry, M. See Francois, A.
Bertoli, Luigi See Yeilding, Allen
Beuzeboc, P. See Garcia-Giralt, E.
Bezwoda, Werner R. See Stein, Moshe E.
Bianco, Angelo Raffaele See Gridelli, Cesare
Blanke, Charles
—Loehrer, Patrick J.; Nichols, Craig R.; Einhorn, Lawrence H.: Phase II trial of VP-16, ifosfamide, cisplatin, vinblastine, and bleomycin in advanced germ-cell tumors, 487
Blessing, John A. See Asbury, Robert
See Look, Katherine Y.
See Malfetano, John H.
Blomqvist, Carl. See Muhonen, Timo
Bloom, Elana J. See deMagalhaes-Silverman, Margarida
Bonadonna, G. See Zambetti, M.
Boudreau, Robert J. See Lee, Chung K.
Brady, Luther W. See Class, Reiner
See Emrich, Jacqueline G.
Brand, William N. See LaCombe, Michael A.
Brandon, Alfred H. See Abitbol, Andre A.
Brannon, William. See Williamson, Stephen K.
Brodsky, Jeffrey
—Abcar, Antoine; Styler, Michael: Splenectomy for non-Hodgkin's lymphoma, 558
Bromberg, Cheryl. See Remick, Scot C.
Burish, Thomas G. See Morrow, Gary R.
Bushunow, Peter W. See Sparano, Joseph A.
Bycott, Paul W. See Schneider, Scott B.

Camel, H. Marvin. See Grigsby, Perry W.
Carle, Flavia. See Giorgi, Francesca
Carlini, P. See Di Costanzo, F.
Carulla, J. See Bellmunt, J.
Cascinu, Stefano
—Del Ferro, Elena; Catalano, Giuseppina: Toxicity and therapeutic response to chemotherapy in patients aged 70 years or older with advanced cancer, 371
Case, L. Douglas. See Atkins, James N.
Castaldi, J. See Leone, B.
Catalano, Giuseppina. See Cascinu, Stefano
Çelik, Ismail. See Barişta, Ibrahim
Cellerino, Riccardo. See Giorgi, Francesca
Chadha, Manjeet. See Yu, Lio
Chaitchik, Samario See Merimsky, Ofer
See Reider-Groswasser, Irith
See Ron, Ilan G.
Chandler, Kym L. See Prados, Michael D.
Chao, Tzu-Chieh. See Lin, Jen-Der
Chastang, Claude. See Bellissant, Eric
Chatikhine, V.A. See Francois, A.
Chen, De-lin. See Hu, Wei-han
Chen, Shande. See Robert, Francisco
Cheong, Seong Kyoon. See Kim, Yeul Hong
Chevallier, B. See Francois, A.
Chevrier, A. See Francois, A.
Chmura, Mary. See Remick, Scot C.
Choi, Jin-Hyuk
—Chun, Hyun Cheol; Yoo, Nae Chun; Lee, Hye Ran; Lee, Kyung Hee; Kim Joo-Hang; Roh, Jae Kyung; Park, Cheong Soo; Min, Jin Sik; Lee, Kyong Sik; Kim, Byung Soo; Lim, Ho Yeong: Gastric cancer in young patients who underwent curative resection. Comparative study with older patients, 45
Choi, Soon Mi. See Kim, Jae Wook
Chun, Hyun Cheol. See Choi, Jin-Hyuk
Cirrone, Joseph. See Aziz, Hassan
Class, Reiner
—Lindman, Sissel; Fassbender, Cordula; Leinenbach, Hans-Peter; Rawer, Stefan; Emrich, Jacqueline G.; Brady, Luther W.; Zeppezauer, Michael: Histone H1 suppresses tumor growth of leukemia cell in vitro, ex vivo, and in an animal model suggesting extracellular functions of histones, 522
See Emrich, Jacqueline G.
Cockey, George H.
—Amann, Stephen T.; Reents, Stan B.; Lynch, James W. Jr.: Stevens-Johnson syndrome resulting from whole-brain radiation and phenytoin, 32
Cocquyt, V.
—Pipeleers-Marichal, M.; Delvaux, G.; Van Belle, S.: Increasing serum-levels of alpha-fetoprotein in a patient with relapsing gallbladder carcinoma, 465
Colangelo, Laura A. See LaCombe, Michael A.
Colozza, M.
—Gori, S.; Mosconi, A.M.; Anastasi, P.; De Angelis, V.; Giansanti, M.; Mercati, U.; Aristei, C.; Latini, P.; Tonato, M.: Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide in a combined modality approach for locally advanced and inflammatory breast cancer, 10
Colucci, Giuseppe. See Gebbia, Vittorio
Constine, Louis S. III. See Simpson, Joseph R.
Conte, Pierfranco. See Michelotti, Andrea
Corn, Benjamin W.
—Hernandez, Enrique; Anderson, Lisa; Fein, Douglas A.; Dunton, Charles J.; Heller, Paul: Phase I/II study of concomitant irradiation and carboplatin for locally advanced carcinoma of the uterine cervix: an interim report, 317. Intermediate-risk endometrial cancer: A management approach, 631
Cornett, Mark S.
—Paris, Kristie J.; Spanos, William J. Jr; Lindberg, Robert D.; Jose, Baby: Radiation therapy for pituitary adenomas. A retrospective study of the University of Louisville experience, 292
Cramer, Michael B. See Yeilding, Allen
Crawford, E. David. See Williamson, Stephen K.
Creagan, E.T. See Frytak, S.
See Shaw, E.G.
Cuevas, M. See Vallejo, C.
Cuevas, M.A. See Leone, B.
Curcio, Carlo. See Gridelli, Cesare
Curran, Walter J. See Simpson, Joseph R.
Cvitkovic, Esteban. See Bensmaine, Mohamed-El-Amine

D'Aprile, Modesto. See Gridelli, Cesare
De Angelis, V. See Colozza, M.
De Castro, J. See Feliu, J.
DeConti, Ronald C. See Remick, Scot C.
De Grandi, Pierre See Delaloye, Jean-Francois
de la Gándara, I. See Feliu, J.
Delaloye, Jean-Francois
—Leyvraz, Serge; Adjahoto, Etsé Outcha; De Grandi, Pierre: Salvage chemotherapy with mitomycin, vindesine, and cisplatin (MiViP) in recurrent carcinoma of the cervix, 204
Del Ferro, Elena. See Cascinu, Stefano
Delgado, Juan Ramon. See Alba, Emilio
Delpech, B. See Francois, A.
Delvaux, G. See Cocquyt, V.
deMagalhaes-Silverman, Margarida
—Rybka, Witold B.; Lembersky, Barry; Bloom, Elana J.; Lister, John; Pincus, Steven M.; Voloshin, Michael; Wilson, John; Ball, Edward D.: High-dose cyclophosphamide, carboplatin, and etoposide with autologous stem cell rescur in patients with breast cancer, 169
Demmy, Todd L. See Abadir, Rushdy
DePierre, A. See Jacoulet, P.
De Torres, J.A. See Bellmunt, J.
Deutsch, Melvin. See Karasek, Kristina
Díaz, J. See Feliu, J.
Di Costanzo, F.
—Tagliaventi, M.; Carlini, P.; Zironi, S.; Mazzocchi, B.; Bella, M.; Donati, D.; Acito, L.; Maggian, P.; Angiona, S.: High-dose folinic acid and fluorouracil with or without ifosfamide is an inactive combination in advanced pancreatic cancer. Randomized Phase II study

of the Italian Oncology Group for Clinical Research (G.O.I.R.C.), 307
Dieras, V. See Garcia-Giralt, E.
Di Lullo, Liberato. See Recchia, Francesco
Dimery, Isaiah W. See Huber, Martin H.
Dimitriades, M. See Pectasides, D.
Domenge, Christian. See Bensmaine, Mohamed-El-Amine
Domenico, Don. See Konski, Andre A.
Dominguez, M. See Vallejo, C.
Donati, D. See Di Costanzo, F.
Dorval, T. See Garcia-Giralt, E.
Douglass, Harold O. Jr. See Meropol, Neal J.
Driscoll, Deborah. See Fine, Bruce A.
Dunnington, Joel S. See Huber, Martin H.
Dunton, Charles J. See Corn, Benjamin W.
Dutcher, Janice P. See Sparano, Joseph A.

Eagan, R.T. See Frytak, S.
See Shaw, E.G.
Ebbert, Larry P. See Edmonson, John H.
Economides, N. See Pectasides, D.
Edelman, Scott. See Aziz, Hassan
Edmonson, John H.
—Ebbert, Larry P.; Nascimento, Antonio G.; Jung, Sin-Ho; McGaw, Hrry; Gerstner, James B.: Phase II study of docetaxel in advanced soft tissue sarcomas, 574
Edwards, Creighton L. See Wright-Browne, Vance
Eggleston, William. See Konski, Andre A.
Eijkenboom, Wilhelmina M.H. See Levendag, Peter C.
Einhorn, Lawrence H. See Blanke, Charles
Eisenberg, Peter. See Yeilding, Allen
Eisenberger, Mario A. See Williamson, Stephen K.
Emrich, Jacqueline G.
—Bender, Hans; Class, Reiner; Eshleman, Jeffrey; Miyamoto, Curtis; Brady, Luther W.: In vitro evaluation of iodine-125-labeled monoclonal antibody (MAb 425) in human high-grade glioma cells, 601
See Class, Reiner
Erhardt, Johannes. See Grabenbauer, Gerhard G.
Erlichman C.
—Fine, S.; Kerr, I.; Hoffmann, W.; Gorg, C.; Schmoll, H.J.; Preusser, P.; Thuerlimann, B.; Gustavsson, B.: A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer, 26
Eshleman, Jeffrey See Emrich, Jacqueline G.
Esper, Peggy S. See Pienta, Kenneth J.
Espinosa, E. See Feliu, J.
Espinosa, J. See Feliu, J.
Ezawa, Kazuhiro. See Nakano, Hidehiko

Fabiani, Francesco. See Recchia, Francesco
Falkson, Carla I.
—Fludarabine: A phase II trial in patients with previously treated low-grade lymphoma, 268
Fanini, Rodolfo. See Recchia, Francesco
Fassbender, Cordula. See Class, Reiner
Fein, Douglas A. See Corn, Benjamin W.
Feldman, I. See Merimsky, O.
Feliu, J.
—González Baron, M.; Garcia Girón, C.; Espinosa, E.; Vicent, J.M.; Gómez Navarro, J.; Berrocal, A.; Ordóñez, A.; Vilches, Y.; de Castro, J.; Díaz, J.: Phase II study of cisplatin, 5-fluorouracil, and leucovorin in inoperable squamous cell carcinoma of the esophagus, 577
—González-Barón, M.; Espinosa, E.; de Castro, J.; Ordoñez, A.; Zamora, P.; Gómez-Navarro, J.; Espinosa, J.; Vilches, Y.; de la Gádnara, I.: Cisplatin and UFT modulated with leucovorin for treatment of advanced non-small-cell lung cancer, 121
Fenoglio-Preiser, Cecilia M. See Hoffelfinger, Sue C.
Ferranti, C. See Zambetti, M.
Ferreyra, R. See Leone, B.
Ferrone, Soldano. See Merimsky, Ofer
Fetten, James V. See Attivissimo, Lori A.
Feun, Lynn G.
—Savaraj, Niramol; Solomon, Jeanine; Liebmann, Amy; Hurley, Judith:Phase II trial of mitoxantrone and cisplatin in advanced non-small-cell lung cancer, 190
Fine, Bruce A.
—Piver, M. Steven; McAuley, Michael; Driscoll, Deborah: The curative potential of radiation therapy in the treatment of primary vaginal carcinoma, 39
Fine, S. See Erlichman C.
Finer, Paul T.
—Microwave thermoradiotherapy for intraocular melanoma, 281
Firat, Dinçer. See Barişta, Ibrahim
Fischbach, A. Jennifer. See Simpson, Joseph R.
Fishman, Pnina. See Merimsky, Ofer
Flaherty, Lawrence E.
—Liu, P.Y.; Mitchell, Malcolm S.; Fletcher, William S.; Walker, Michael J.; Goodwin, John Wendall; Stephens, Ronald L.; Sondak, Vernon K.: Addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. Phase II trial of the Southwest Oncology Group, 108
See Pienta, Kenneth J.
Fleckman, Adrienne M. See Yu, Lio
Fletcher, William S. See Flaherty, Lawrence E.
Flynn, Patrick J. See Sparano, Joseph A.
Focaccia, G. See Leone, B.
Foote, R.L. See Frytak, S.
See Shaw, E.G.
Fountzilas, G. See Bafaloukos, D.
See Pectasides, D.
Fracchia, John A. See Miller, Lawrence S.
Fraley, Elwin E. See Kennedy, B.J.
Francois, A.
—Chatikhine, V.A.; Chevallier, B.; Sheng Ren, G.; Berry, M.; Chevrier, A.; Delpech, B.: Letter to the Editor, 322
Frei, Emil III. See Lasagna, Louis
Fried, Jetta. See Stein, Moshe E.
Fruchter, Rachel. See Aziz, Hassan
Frytak, S.
—Shaw, E.G.; Jett, J.R.; Richardson, R.L.; Foote, R.L.; Creagan, E.T.; Eagan, R.T.; Su, J.Q.: Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small-cell lung cancer, 193
See Shaw, E.G.
Fu, Yao S. See Mark, Rufus J.
Fueki, Naoto. See Nakano, Hidehiko

Galakatos, Andrew E. See Grigsby, Perry W.
Galetta, Domenico. See Gebbia, Vittorio
Gallup, Donald G. See Look, Katherine Y.
Ganssauge, Friederike. See Plasswilm, Ludwig
García Girón, C. See Feliu, J.
Garcia-Giralt, E.
—Beuzeboc, P.; Dieras, V.; Dorval, T.; Jouve, M.; Livartowski, A.; Palangie, T.; Scholl, S.; Pouillart, P.: Phase II trial of decapeptyl (D-TRP-6), a potent luteinizing hormone-releasing hormone analogue in untreated advanced breast cancer, 455
Gebbia, Nicolo. See Gebbia, Vittorio
Gebbia, Vittorio
—Galetta, Domenico; Majello, Evaristo; Valenza, Roberto; Colucci, Giuseppe; Gebbia, Nicolo: Treatment of stage III-IV non-small-cell lung carcinoma with vinorelbine in combination with ifosfamide plus MESNA: A study by the Southern Italy Oncology Group (GOIM), 278
See Gridelli, Cesare
Gerstner, James B. See Edmonson, John H.
Giannakakis, T. See Bafaloukos, D.
Giannessi, Piergiogrio See Michelotti, Andrea
Giansanti, M. See Colozza, M.
Giordani, Paolo. See Giorgi, Francesca
Giorgi, Francesca
—Cellerino, Riccardo; Gramazio, Attilio; Tummarello, Diego; Menichetti, Ettore Tito; Giordani, Paolo; Antognoli, Stefania; Carle, Flavia;

Piga, Andrea: Assessing quality of life in patients with cancer: A comparison of a visual-analogue and a categorical model, 394
Gogou, L. See Pectasides, D.
Gómez Navarro, J. See Feliu, J.
Gondo, Hiroshi. See Kondo, Yukifumi
González-Barón, M. See Feliu, J.
Goodwin, John Wendall. See Flaherty, Lawrence E.
Gordon, Leo I. See LaCombe, Michael A.
Gorg, C. See Erlichman C.
Gori, S. See Colozza, M.
Grabenbauer, Gerhard G
—Beck, Jorn D.; Erhardt, Johannes; Seegenschmiedt, M. Heinrich; Seyer, Hendrikus; Thierauf, Paul; Sauer, Rolf: Postoperative radiotherapy of medulloblastoma. Impact of radiation quality on treatment outcome, 73
Grado, Gordon L. See Halyard, Michele Y.
Graham, Mary V. See Grigsby, Perry W.
Gramazio, Attilio. See Giorgi, Francesca
Grant, Clive S. See Halyard, Michele Y.
Gridelli, Cesare
—D'Aprile, Modesto; Palmeri, Sergio; Curcio, Carlo; Rossi, Antonio; Gebbia, Vittorio; Veltri, Enzo; Pepe, Rosario; Pistillucci, Giorgio; Bianco, Angelo Raffaele: Phase I study of chemotherapy wit carboplatin, epirubicin, and escalating dose of VP-16 with G-CSF support in extensive small cell lung cancer, 589
Grigsby, Perry W.
—Graham, Mary V.; Perez, Carlos A.; Galakatos, Andrew E.; Camel, H. Marvin; Kao, Ming-Shian: Prospective phase I/II studies of definitive irradiation and chemotherapy for advanced gynecologic malignancies, 1
Groshen, Susan L. See Moyses, Harry M.
Grote, Thomas. See Atkins, James N.
Guillot, Thierry. See Bensmaine, Mohamed-El-Amine
Güler, Nilüfer. See Barişta, Ibrahim
Güllü, Ibrahim H. See Barişta, Ibrahim
Gustavsson, B. See Erlichman C.

Haghbin, Mahroo
—McCue, Peter A.; Mansfield, Carl M.; Komarnicky, Lydia T.; Benammar, Alia; Schwartz, Gordon F.: Correlation of flow cytometry to clinical factors, hormone receptors, and histopathological grade in stage I and II invasive breast carcinoma, 54
Hahne, William F. See Yeilding, Allen
Haller, Daniel G. See Vaughn, David J.
Halyard, Michele Y.
—Grado, Gordon L.; Schomberg, Paula J.; Weaver, Amy L.; Grant, Clive S.; Pisansky, Thomas M.: Conservative therapy of breast cancer. The Mayo Clinic experience, 445
Hamano, K. See Takahashi, T.
Hansen, Richard. See Sparano, Joseph A.
Harnett, P.R. See Witham, M.
Harper, Gregory R. See Remick, Scot C.
Hase, Taiji. See Kondo, Yukifumi
Healey, Barbara. See Remick, Scot C.
Heaps, James. See Mark, Rufus J.
Hebert, Mary E.
—Lowe, Val J.; Hoffman, John M.; Patz, Edward F.; Anscher, Mitchell S.: Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: Preliminary findings, 416
Heller, Paul. See Corn, Benjamin W.
Hernandez, Enrique. See Corn, Benjamin W.
Hickok, Jane T. See Morrow, Gary R.
Higashi, Tsunechi. See Kondo, Yukifumi
Hilstro, Jane. See Remick, Scot C.
Ho, Yat-Sen. See Lin, Jen-Der
Hoffelfinger, Sue C.
—Lower, Elyse E.; Miller, Mary Ann; Fenoglio-Preiser, Cecilia M.:Plasma membrane phosphotyrosine, Her2-NEU, and epidermal growth factor receptor in human breast cancer. A comparative study, 552
Hoffman, John M. See Hebert, Mary E.
Hoffmann, W. See Erlichman C.
Homel, Peter. See Aziz, Hassan
Homesley, Howard D. See Malfetano, John H.
Hong, Waun Ki. See Huber, Martin H.
Hortobagyi, Gabriel N. See Anderson, Clay M.
Horton, John. See Remick, Scot C.
Hoshino, Hideki. See Nakano, Hidehiko
Hoskins, P.J. See Woo, H.L.
Hosokawa, Masuo. See Kondo, Yukifumi
Houdek, Pavel V. See Abitbol, Andre A.
Hsu, Chen-Yi. See Lin, Jin-Ching
Hsu, Wen-Lin
—Shueng, Pei-Wei; Jen, Yee-Min; Wu, Ching-Jung; Liu, Hang-Seng; Su, Chih-Chung; Hwang, Jing-Min: Concurrent 5-fluorouracil, daily low-dose cisplatin, and radiotherapy in stage IIIB cervical cancer. A phase II prospective study, 263
Hu, Wei-han
—Chen, De-lin; Min, Hua-qing: Study of 45 cases of nasopharyngeal carcinoma with dermatomyositis, 35
Huang, Hong-So. See Lin, Jen-Der
Huber, Martin H.
—Lippman, Scott M.; Benner, Steven E.; Shirinian, Mihran; Dimery, Isaiah W.; Dunnington, Joel S.; Hong, Waun Ki: Phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck, 379
Huberman, Mark. See Stuart, Keith
Hurley, Judith. See Feun, Lynn G.
Hussain, Fazal. See Aziz, Hassan
Hutchinson, Raymond J. See Sisson, James C.
Hwang, Jing-Min. See Hsu, Wen-Lin

Inbar, Moshe J. See Ron, Ilan G.
Irving, Douglas. See Konski, Andre A.
Ishihara, Hiroshi. See Kigawa, Junzo
Ishihara, Shin-ichi. See Nakano, Hidehiko
Ishii, Eiichi
—Matsuzaki, Akinobu; Ohnishi, Yoshitaka; Kai, Takeshi; Ueda, Kohji: Successful treatment with ranimustine and carboplatin for recurrent intraocular retinoblastoma with vitreous seeding, 562
Itamochi, Hiroaki. See Kigawa, Junzo

Jacoulet, P.
—Maheu, M.F.; Loire, R.; Saugier, B.; DePierre, A.: Long-term cure of non-small-cell lung cancer treated by monochemotherapy, 260
Jan, Jian-Sheng. See Lin, Jin-Ching
Janot, Francois. See Bensmaine, Mohamed-El-Amine
Jansen, Peter P. See Levendag, Peter C.
Jantunen, Ismo. See Muhonen, Timo
Jekunen, Antti
—Kairemo, Kalevi J.A.; Lehtonen, Hannu P.; Kajanti, Mikael J.: Treatment of olfactory neuroblastoma. A report of 11 cases, 375
—Pyrhönen, Seppo: A combination of vinblastine and doxorubicin with interferon alpha, 384
Jen, Yee-Min. See Hsu, Wen-Lin
Jett, J.R. See Frytak, S.
See Shaw, E.G.
Jose, Baby. See Cornett, Mark S.
Jouve, M. See Garcia-Giralt, E.
Jung, Sin-Ho. See Edmonson, John H.

Kagan, A. Robert
—Editorial, 636
—Steckel, Richard J.: Palliation, 532
Kai, Takeshi. See Ishii, Eiichi
Kairemo, Kalevi J.A. See Jekunen, Antti P.
Kajanti, Mikael J. See Jekunen, Antti P.
Kanamori, Yasunobu. See Kigawa, Junzo
Kao, Ming-Shian. See Grigsby, Perry W.
Karasek, Kristina
—Deutsch, Melvin: Lumpectomy and breast irradiation for breast cancer after radiotherapy for lymphoma, 451

Karminsky, Nataly. See Reider-Groswasser, Irith
Kars, Ayşe. See Barişta, Ibrahim
Kato, T. See Takahashi, T.
Kavanagh, John J. See Wright-Browne, Vance
Kellokumpuu-Lehtinen, Pirkko. See Muhonen, Timo
Kelsen, David P. See Meropol, Neal J.
Kennedy, B.J.
—Torkelson, Jane L.; Fraley, Elwin E.: Adequacy of chemotherapy prior to cytoreductive surgery in testicular carcinoma, 541
Kenyon, Lawrence C. See Arepally, Gowthami
Kerr, I. See Erlichman C.
Khojasteh, Ali. See Yeilding, Allen
Kigawa, Junzo
—Minagawa, Yukihisa; Ishihara, Hiroshi; Itamochi, Hiroaki; Kanamori, Yasunobu; Terakawa, Naoki: The role of neoadjuvant intraarterial infusion chemotherapy with cisplatin and bleomycin for locally advanced cervical cancer, 255
Kim, Byung Soo. See Choi, Jin-Hyuk
Kim, Dong Kyu. See Kim, Jae Wook
Kim, Harold. See LaCombe, Michael A.
Kim, Jae Wook
—Kim, Young Tae; Choi, Soon Mi; Kim, Dong Kyu; Song, Chan Ho: Effect of 13-cis-retinoic acid with neoadjuvant chemotherapy in patients with squamous cervical carcinoma, 442
Kim, Joo-Hang. See Choi, Jin-Hyuk
Kim, Jun Suk. See Kim, Yeul Hong
Kim, Yeul Hong
—Cheong, Seong Kyoon; Lee, Jee Dong; Park, Jeong Sik; Shin, Sang Won; Kim, Jun Suk: Phase II trial of oral UFT and leukovorin in advanced gastric carcinoma, 212
Kim, Young Tae. See Kim, Jae Wook
Kirkwood, John. See Sparano, Joseph A.
Kirschner, Michael J. See Schuchardt, Ulrike
Klement, Vaclav. See Moyses, Harry M.
Klonaris, C. See Tsavaris, N.B.
Klouvas, G. See Bafaloukos, D.
Kobayashi, Hiroshi. See Kondo, Yukifumi
Kodaira, S. See Takahashi, T.
Komarnicky, Lydia T. See Haghbin, Mahroo
Kondo, Yukifumi
—Uchino, Junichi; Sawaguchi, Yuji; Shirato, Hiroshi; Gondo, Hiroshi; Hase, Taiji; Saito, Isao; Higashi, Tsuneshi; Hosokawa, Masuo; Kobayashi, Hiroshi: Evaluation of multi skin test in colorectal cancer patients and effects of serum immunosuppressive factor and cytokine production of peripheral mononuclear cells, 159
Konski, Andre A.
—Domenico, Don; Irving, Douglas; Tyrkus, Michael; Neisler, James; Phibbs, Garth; Mah, John; Eggleston, William: Clinicopathologic correlation of DNA flow cytometric content analysis, surgical staging, and estrogen/progesterone receptor status in endometrial adenocarcinoma, 164
Physician involvement and assessment in the development of hospitaloncology programs, 311
Kosmas, C. See Tsavaris, N.B.
Kosmidis, P. See Bafaloukos, D.
See Pectasides, D.
See Tsavaris, N.B.
Koyama, Y. See Takahashi, T.
Kreis, Willi. See Attivissimo, Lori A.
Kudelka, Andrzej P. See Wright-Browne, Vance

Lacava, J. See Leone, B.
See Vallejo, C.
LaCombe, Michael A.
—Mittal, Bharat B.; Colangelo, Laura A.; Rademaker, Alfred W.; Brand, William N.; Kim, Harold; Gordon, Leo I.; Merrill, John M.: Management of early-stage Hodgkin's lymphoma. The Radiation Oncology Experience at Northwestern University.Northwestern Memorial Hospital, 235
Lai, Gi-Ming. See Yang, Tsai-Shen
Lalli, Angelo. See Recchia, Francesco
Langhi, M. See Vallejo, C.
Lasagna, Louis
—Frei, Emil III: Impact of regulations, tradition, and experimental design on clinical cancer trials: Report and recommendations resulting from Washington Cancer Trials Conference, 325
Latini, P. See Colozza, M.
See Maranzano, Ernesto
Lauer, Stephen J. See Rock, Douglas B.
Laufer, Karen A. See Abitbol, Andre A.
Lavi, Ehud See Arepally, Gowthami
Lee, Beverly C. See Robert, Francisco
Lee, Chung K.
—Aeppli, Dorothee M.; Unger, Judy; Boudreau, Robert J.; Levitt, Seymour H.: Strontium-89 chloride (Metastron) for palliative treatment of bony metastases: the University of Minnesota experience, 102
—Levitt, Seymour H.: Long-term follow-up of pathologic stage I large cell non-Hodgkin's lymphoma patients after primary radiotherapy, 93
Lee, Hye Ran See Choi, Jin-Hyuk
Lee, Jee Dong. See Kim, Yeul Hong
Lee, Kyong Sik. See Choi, Jin-Hyuk
Lee, Kyung He. See Choi, Jin-Hyuk
Lee, R.E. See Shaw, E.G.
Lehtonen, Hannu P. See Jekunen, Antti P.
Leinenbach, Hans-Peter. See Class, Reiner
Lembersky, Barry. See deMagalhaes-Silverman, Margarida
Lentz, Sam S. See Look, Katherine Y.
Leone, B.
—Vallejo, C.; Perez, J.; Cuevas, M.A.; Machiavelli, M.; Lacava, J.; Focaccia, G.; Ferreyra, R.; Suttora, G.; Romero, A.; Castaldi, J.; Arroyo, A.; Rabinovich, M.: Ifosfamide and cisplatin as neoadjuvant chemotherapy for advanced cervical carcinoma, 132
See Vallejo, C.
Levendag, Peter C.
—Nowak, Peter J.C.M.; Van der Sangen, Maurice J.C.; Jansen, Peter P.; Eijkenboom, Wilhelmina M.H.; Planting, Andre S, Th.; Meeuwis, Cees A.; van Putten, Wim L.J.: Local tumor control in radiation therapy of cancers in the head and neck, 469
Levetan, Claresa. See Yu, Lio
Levitt, Seymour H. See Lee, Chung K.
Lewin, Alan A. See Abitbol, Andre A.
Leyvraz, Serge. See Delaloye, Jean-Francois
Liaw, Chuang-Chi. See Yang, Tsai-Shen
Liebmann, Amy. See Feun, Lynn G.
Liggett, Peter E. See Petrovich, Zbigniew
Lim, Ho Yeong. See Choi, Jin-Hyuk
Lin, Jen-Der
—Chao, Tzu-Chieh; Weng, Hsiao-Fen; Huang, Hong-So; Ho, Yat-Sen: Clinical presentations and treatment for 74 occult thyroid carcinoma. Comparison with nonoccult thyroid carcinoma in Taiwan, 504
Lin, Jin-Ching
—Jan, Jian-Sheng; Hsu, Chen-Yi: Preliminary report of outpatient weekly adjuvant chemotherapy for high-risk nasopharyngeal carcinoma, 624
Lindberg, Robert D. See Cornett, Mark S.
Lindman, Sissel. See Class, Reiner
Lippman, Scott M. See Huber, Martin H.
Lipsitz, Stuart. See Sparano, Joseph A.
Lisaios, B. See Tsavaris, N.B.
Lister, John.. See deMagalhaes-Silverman, Margarida
Liu, Hang-Seng. See Hsu, Wen-Lin
Liu, P.Y. See Flaherty, Lawrence E.
Livartowski, A. See Garcia-Giralt, E.
Loehrer, Patrick J. See Blanke, Charles
Loire, R. See Jacoulet, P.
Lombardo, Marco. See Recchia, Francesco
Look, Katherine Y.
—Blessing, John A.; Gallup, Donald G.; Lent, Sam S.: Phase II trial of 5-fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study, 439
See Malfetano, John H.

Lopez-Pacios, M.A. See Bellmunt, J.
Lowe, Val J. See Hebert, Mary E.
Lower, Elyse E. See Hoffelfinger, Sue C.
Lupattelli, Marco. See Maranzano, Ernesto
Luxton, Gary. See Petrovich, Zbigniew
Lynch, James W., Jr. See Cockey, George H.

Machiavelli, M. See Leone, B.
See Vallejo, C.
Mack, Ellen E. See Prados, Michael D.
Maggian, P. See Di Costanzo, F.
Mah, John. See Konski, Andre A.
Maheu, M.F. See Jacoulet, P.
Maiche, Abdel See Muhonen, Timo
Maio, Michele. See Merimsky, Ofer
Majello, Evaristo. See Gebbia, Vittorio
Makimoto, Takeyuki. See Nakano, Hidehiko
Makrantonakis, P. See Bafaloukos, D.
Malec, Mary. See Prados, Michael D.
Malfetano, John H.
—Blessing, John A.; Homesley, Howard D.; Look, Katherine Y.; McGehee, Ramon: Phase II trial of didemnin B (NSC #335319) in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study, 184
Malpica, Anais. See Wright-Browne, Vance
Mandrekois, D. See Tsavaris, N.B.
Mani, Sridhar
—Poo, Wen-Jen: Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma, 149
—Todd, Mary; Poo, Wen-Jen: Recombinant beta-interferon in the treatment of patients with metastatic renal cell carcinoma, 187
Mansfield, Carl M. See Haghbin, Mahroo
Maranzano, Ernesto
—Latini, Paolo; Beneventi, Sara; Perrucci, Elisabetta; Panizza, Bianca Moira; Aristei, Cynthia; Lupattelli, Marco; Tonato, Maurizio: Radiotherapy without steroids in selected metastatic spinal cord compression patients, 179
Mark, Rufus J.
—Poen, Joseph; Tran, Luu M.; Fu, Yao S.; Heaps, James; Parker, Robert G.: Postirradiation sarcoma of the gynecologic tract. Report of 13 cases and discussion of the risk of radiation-induced gynecologic malignancies, 59
Markoe, Arnold M. See Abitbol, Andre A.
Marmur, Sylvia. See Ron, Ilan G.
Matsuzaki, Akinobu. See Ishii, Eiichi
Mazzocchi, B. See Di Costanzo, F.
McAuley, Michael. See Fine, Bruce A.
McCue, Peter A. See Haghbin, Mahroo
McFarland, James. See Atkins, James N.
McGaw, Harry. See Edmonson, John H.
McGehee, Ramon. See Malfetano, John H.
Meehan, Rosemary. See Ampil, Federico L.
Meeuwis, Cees A. See Levendag, Peter C.
Menichetti, Ettore Tito. See Giorgi, Francesca
Mercati, U. See Colozza, M.
Merimsky, Ofer
—Fishman, P.; Feldman, I.; Shafir, R.; Rapaport, Y.; Sheonfeld, Y.; Chaitchik, S.: Malignant melanoma of the head and neck. Clinical and immunological considerations, 363
—Shoenfeld, Yehuda; Baharav, Ehud; Altomonte, Maresa; Chaitchik, Samario; Maio, Michele; Ferrone, Soldano; Fishman, Pnina: Melanoma-associated hypopigmentation: Where are the antibodies? 613
See Reider-Groswasser, Irith
Meropol, Neal J.
—Pazdur, Richard; Vincent, Mark; Willson, James K.V.; Kelsen, David P.; Douglass, Harold O. Jr.: Phase II study of ZD1694 in patients with advanced gastric cancer, 628
See Vaughn, David J.
Merrill, John M. See LaCombe, Michael A.
Michelotti, Andrea
—Romanini, Antonella; Giannessi, Piergiorgio; Conte, Pierfranco: Accelerated epirubicin-ifosfamide-dacarbazine regimen in patients with adult soft tissue sarcomas, 78
Miller, Antonius A. See Robert, Francisco
Miller, Lawrence S.
—Armenakas, Noel A.; Motta, Joseph; Fracchia, John A.: PSA divergence. A new parameter for the accurate longitudinal assessment of prostatic disease, 217
Miller, Mary Ann. See Hoffelfinger, Sue C.
Min, Hua-qing. See Hu, Wei-han
Min, Jin Sik. See Choi, Jin-Hyuk
Minagawa, Yukihisa. See Kigawa, Junzo
Minamia, Hironobu. See Ando, Yuichi
Minato, Koichi. See Nakano, Hidehiko
Miser, Angela W. See Sandlund, John T.
Miser, James S. See Sandlund, John T.
Mitchell, Malcolm S. See Flaherty, Lawrence E.
Mittal, Bharat B. See LaCombe, Michael A.
Miyamoto, Curtis. See Emrich, Jacqueline G.
Modiano, Manuel R. See Yeilding, Allen
Molthrop, David C. See Robert, Francisco
Moore, David. See Asbury, Robert
Mori, Masatomo. See Nakano, Hidehiko
Morote, J. See Bellmunt, J.
Morrow, C. Paul. See Moyses, Harry M.
Morrow, Gary R.
—Hickok, Jane T.; Burish, Thomas G.; Rosenthal, Susan N.: Frequency and clinical implictions of delayed nausea and delayed emesis, 199
Mosconi, A.M. See Colozza, M.
Motta, Joseph. See Miller, Lawrence S.
Moyses, Harry M.
—Morrow, C. Paul; Muderspach, Laila I.; Roman, Lynda D.; Vasilev, Steven A.; Petrovich, Zbigniew; Groshen, Susan L.; Klement, Vaclav: Residual disease in the uterus after preoperative radiotherapy and hysterectomy in stage IB cervical carcinoma, 433
Muderspach, Laila I. See Moyses, Harry M.
Muhonen, Timo
—Jantunen, Ismo; Pertovaara, Hannu; Voutilainen, Leena; Maiche, Abdel; Blomqvist, Carl; Pyrhönon, Seppo; Kellokumpu-Lehtinen, Pirkko: Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer, 232
Murphree, Alan L. See Petrovich, Zbigniew
Murray, Kevin J. See Rock, Douglas B.
Muss, Hyman B. See Atkins, James N.
Mylonakis, N. See Tsavaris, N.B.

Nakano, Hidehiko
—Tsuchiya, Satoshi; Takei, Yoshikazu; Minato, Koichi; Watanabe, Satoru; Makimoto, Takeyuki; Naruse, Ichiro; Nomoto, Taisuke; Ishihara, Shin-ichi; Takise, Atsushi; Ezawa, Kazuhiro; Fueki, Naoto; Hishino, Hideki; Saito, Ryusei; Mori, Masatomo: Phase I study of a carboplatin-cisplatin-etoposide combination chemotherapy in advanced non-small-cell lung cancer, 245
Nanda, Anil. See Ampil, Federico L.
Nandy, Indrani. See Ampil, Federico L.
Naruse, Ichiro. See Nakano, Hidehiko
Nascimento, Antonio G. See Edmonson, John H.
Neisler, James. See Konski, Andre A.
Ng, Kim-Thean. See Yang, Tsai-Shen
Nichols, Craig R. See Blanke, Charles
Nicolaides, C. See Pectasides, D.
Nomoto, Taisuke. See Nakano, Hidehiko
Nomura, Fumio. See Ando, Yuichi
Nowak, Peter J.C.M. See Levendag, Peter C.
Nuzzo, Antonio. See Recchia, Francesco

Ogawa, N. See Takahashi, T.
Ohnishi, Yoshitaka. See Ishii, Eiichi
Ordóñez, A. See Feliu, J.

O'Rourke, Mark A. See Williamson, Stephen K.
Ortiz, E. See Vallejo, C.
Ozişik, Yavu. See Barişta, Ibrahim

Page, Margaretta. See Prados, Michael D.
Palangie, T. See Garcia-Giralt, E.
Palmeri, Sergio. See Gridelli, Cesare
Panizza, Bianca Moira. See Maranzano, Ernesto
Paris, Kristie J. See Cornett, Mark S.
Park, Cheong Soo. See Choi, Jin-Hyuk
Park, Jeong Sik. See Kim, Yeul Hong
Parker, Robert G. See Mark, Rufus J.
See Schneider, Scott B.
Patz, Edward F. See Hebert, Mary E.
Pavlidis, N. See Bafaloukos, D.
See Pectasides, D.
Pazdur, Richard. See Meropol, Neal J.
Pectasides, D.
—Bafaloucos, D.; Antoniou, F.; Gogou, L.; Economides, N.; Varthalitis, J.; Dimitriades, M.; Kosmidis, P.; Athanassiou, A.: TPA, TATI, CEA, AFP, ;gb-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder, 271
—Pavlidis, N.; Gogou, L.; Antoniou, F.; Nicolaides, C.; Tsikalakis, D.; Fountzilas, G.: Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients, 459
Pepe, Rosario. See Gridelli, Cesare
Peretti, Giancarlo. See Recchia, Francesco
Perez, Carlos A. See Grigsby, Perry W.
Perez, J. See Leone, B.
See Vallejo, C.
Perrucci, Elisabetta. See Maranzano, Ernesto
Pertovaara, Hannu. See Muhonen, Timo
Petrovich, Zbigniew
—Pike, Malcolm; Astrahan, Melvin A.; Luxton, Gary; Murphree, Alan L.; Liggett, Peter E.: Episcleral plaque thermoradiotherapy of posterioruveal melanomas, 207
See Moyses, Harry M.
Phibbs, Garth. See Konski, Andre A.
Pienta, Kenneth J.
—Redman, Bruce G.; Esper, Peggy S.; Flaherty, Lawrence E.: Phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostate, 500
Piga, Andrea. See Giorgi, Francesca
Pike, Malcolm. See Petrovich, Zbigniew
Pincus, Steven M. See deMagalhaes-Silverman, Margarida
Piotti, P. See Zambetti, M.
Pipeleers-Marichal, M. See Cocquyt, V.
Pisansky, Thomas M. See Halyard, Michele Y.
Pistillucci, Giorgio. See Gridelli, Cesare
Piver, M. See Fine, Bruce A.
Planting, Andre S.Th. See Levendag, Peter C.
Plasswilm, Ludwig
—Seegenschmiedt, M. Heinrich; Ganssauge, Friederike; Sauer, R.: Simultaneous radiochemotherapy for recurrent and metastatic breast carcinoma: Evaluation of two treatment concepts, 403
Plezia, Patricia. See Yeilding, Allen
Poen, Joseph. See Mark, Rufus J.
Poo, Wen-Jen. See Mani, Sridhar
Pouillart, P. See Garcia-Giralt, E.
Prados, Michael D.
—Warnick, Ronald E.; Mack, Ellen E.; Chandler, Kym L.; Rabbitt, Jane; Page, Margaretta; Malec, Mary: Intravenous carboplatin for recurrent gliomas. A dose-escalating phase II trial, 609
Preusser, P. See Erlichman C.
Pyrhönen, Seppo See Jekunen, Antti
See Muhonen, Timo

Rabbitt, Jane. See Prados, Michael D.
Rabinovich, M. See Leone, B.
Rademaker, Alfred W. See LaCombe, Michael A.
Rapaport, Y. See Merimsky, O.
Raub, William A. Jr. See Abitbol, Andre A.
Rawer, Stefan. See Class, Reiner
Recchia, Francesco
—Nuzo, Antonio; Lalli, Angelo; Lombardo, Marco; Di Lullo, Liberato; Fabiani, Francesco; Fanini, Rodolfo; Venturoni, Lanfranco; Torchio, Pierfederico; Peretti, Giancarlo: Randomized trial of 5-fluorouracil and high-dose folinic acid with or without alpha-2B interferon in advanced colorectal cancer, 301
Redman, Bruce G. See Pienta, Kenneth J.
Reents, Stan B. See Cockey, George H.
Reider-Groswasser, Irith
—Merimsky, Ofer; Karminsky, Nataly; Chaitchik, Samario: Computer tomography features of cerebral spread of malignant melanoma, 49
Remick, Scot C.
—Chmura, Mary; Bromberg, Cheryl; Sporn, Jonathan; Healey, Barbara; Hilstro, Jane; DeConti, Ronald C.; Horton, John; Ruckdeschel, John C.; Harper, Gregory R.: Concurrent 72-hour continuous infusion of etoposide and cisplatin in metastatic breast cancer, 125
Renner, Helmut. See Schuchardt, Ulrike
Ribas, A. See Bellmunt, J.
Ribelles, Nuria. See Alba, Emilio
Richards, Frederick I I. See Atkins, James N.
Richardson, R.L. See Frytak, S.
See Shaw, E.G.
Robert, Francisco
—Molthrop, David C.; Miller, Antonius A.; Lee, Beverly C.; Chen, Shande; Wheeler, Richard H.: Prolonged infusion of etoposide in patients with advanced non-small cell lung cancer, 483
Robinson, E. See Zidan, J.
Rock, Douglas B.
—Murray, Kevin J.; Schultz, Christopher J.; Lauer, Stephen J.; Wilson, J. Frank: Stage I and II Hodgkin's disease in the pediatric population. Long-term follow-up of patients staged predominantly clinically, 174
Rodriguez, R. See Vallejo, C.
Roh, Jae Kyung. See Choi, Jin-Hyuk
Roman, Lynda D. See Moyses, Harry M.
Romanini, Antonella. See Michelotti, Andrea
Romero, A. See Leone, B.
See Vallejo, C.
Romero Acuña, J. See Vallejo, C.
Romero Acuña, L. See Vallejo, C.
Ron, Ilan G.
—Amir, Gail; Marmur, Sylvia; Chaitchik, Samario; Inbar, Moshe J.: Kaposi's sarcoma on a lymphedematous arm after mastectomy, 87
Rosenthal, Susan N. See Morrow, Gary R.
Rossi, Antonio. See Gridelli, Cesare
Rotman, Marvin See Aziz, Hassan
See Simpson, Joseph R.
Rovirosa, A. See Bellmunt, J.
Ruacan, Sevket. See Barişta, Ibrahim
Ruckdeschel, John C. See Remick, Scot C.
Rueda, Antonio. See Alba, Emilio
Ruff, Paul. See Stein, Moshe E.
Rybka, Witold B. See deMagalhaes-Silverman, Margarida

Sabatini, C. See Vallejo, C.
Sacks, Evan. See Yu, Lio
Saito, Isao. See Kondo, Yukifumi
Saito, Ryusei. See Nakano, Hidehiko
Sakabe, T. See Takahashi, T.
Sakai, Shuzo. See Ando, Yuichi
Sakelaropoulos, N. See Tsavaris, N.B.
Salimi, Mehrdad
—Spinelli, John J.: Chemotherapy of Mediterranean abdominal lymphoma. Retrospective comparison of chemotherapy protocols in Iranian patients, 18
Salvadori, M. See Vallejo, C.
Salvajoli, Joao Victor. See Weltman, Eduardo

Sánchez-Chaparro, Miguel Angel. See Alba, Emilio
Sandlund, John T.
—Miser, James S.; Miser, Angela W.: Sweet syndrome in a patient with osteosarcoma, 349
Saraçbaşi, Osman. See Barişta, Ibrahim
Sauer, R. See Grabenbauer, Gerhard G.
See Plasswilm, Ludwig
See Schuchardt, Ulrike
Saugier, B. See Jacoulet, P.
Savaraj, Niramol. See Feun, Lynn G.
Sawaguchi, Yuji. See Kondo, Yukifumi
Schaid, D.J. See Shaw, E.G.
Schmoll, H.-J. See Erlichman C.
Schneider, Scott B.
—Schweitzer, Victor G.; Parker, Robert G.; Bycott, Paul W.: The prognostic value of PSA levels in radiation therapy of patients with carcinoma of the prostate: The UCLA experience 1988-1992, 65
Scholl, S. See Garcia-Giralt, E.
Schomberg, Paula J. See Halyard, Michele Y.
Schuchardt, Ulrike
—Seegenschmiedt, M. Heinrich; Kirschner, Micael J.; Renner, Helmut; Sauer, Rolf: Adjuvant radiotherapy for breast carcinoma in men: A 20-year clinical experience, 330
Schultz, Christopher J. See Rock, Douglas B.
Schwartz, Gordon F. See Haghbin, Mahroo
Schweitzer, Victor G. See Schneider, Scott B.
Scott, Charles B. See Simpson, Joseph R.
Seegenschmiedt, M. Heinrich See Grabenbauer, Gerhard G.
See Plasswilm, Ludwig
See Schuchardt, Ulrike
Sevin, Bernd-U. See Abitbol, Andre A.
Seyer, Hendrikus. See Grabenbauer, Gerhard G.
Shafir, R. See Merimsky, O.
Shapiro, Brahm. See Sisson, James C.
Shaw, E.G.
—Frytak, S.; Eagan, R.T.; Richardson, R.L.; Creagan, E.T.; Jett, J.R.; Foote, R.L.; Su, J.Q.; Schaid, D.J.; Lee, R.E.: Etoposide-cisplatin and thoracic radiation therapy salvage of incomplete responders to non-cisplatin induction regimen for limited and extensive small-cell carcinoma of the lung, 154
See Frytak, S.
Sheng Ren, G. See Francois, A.
Sheonfeld, Y. See Merimsky, O.
Shetty, M.R. Letter to the Editor, 322
Shimokata, Kaoru. See Ando, Yuichi
Shin, Sang Won. See Kim, Yeul Hong
Shirato, Hiroshi. See Kondo, Yukifumi
Shirinian, Mihran. See Huber, Martin H.
Shoenfeld, Yehuda. See Merimsky, Ofer
Shpendler, M. See Zidan, J.
Shueng, Pei-Wei. See Hsu, Wen-Lin
Shulkin, Barry L. See Sisson, James C.
Sigal, Robert. See Bensmaine, Mohamed-El-Amine
Simpson, Joseph R.
—Scott, Charles B.; Rotman, Marvin; Curran, Walter J.; Constine, Louis S. III; Fischbach, A. Jennifer; Asbell, Sucha O.: Race and prognosis of brain tumor patients entering multicenter clinical trials. Report from the Radiation Therapy Oncology Group, 114
Sisson, James C.
—Shapiro, Brahm; Hutchinson, Raymond J.; Shulkin, Barry L.; Zempel, Shirley: Survival of patients with neuroblastoma treated with 125-I MIBG, 144
Skarlos, D. See Bafaloukos, D.
Solano, Jose. See Alba, Emilio
Sole, L.A. See Bellmunt, J.
Solomon, Jeanine. See Feun, Lynn G.
Sondak, Vernon K. See Flaherty, Lawrence E.
Song, Chan Ho. See Kim, Jae Wook
Soumilas, A. See Tsavaris, N.B.
Spanos, William J. Jr. See Cornett, Mark S.
Sparano, Joseph A.
—Lipsitz, Stuart; Wadler, Scott; Hansen, Richard; Bushunow, Peter W.; Kirkwood, John; Flynn, Patrick J.; Dutcher, Janice P.; Benson, Al B.: Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292, 546
Sporn, Jonathan. See Remick, Scot C.
Steckel, Richard J. See Kagan, A. Robert
Stein, Moshe E.
—Ruff, Paul, Weaving, Ann; Fried, Jetta; Bezwoda, Werner R.: Phase II study of cisplatin/ifosfamide in recurrent/metastatic undifferentiated nasopharyngeal carcinoma among young blacks in Southern Africa, 386
Stephens, Ronald L. See Flaherty, Lawrence E.
Stuart, Keith
—Tessitore, Judy, Huberman, Mark: 5-Fluorouracil and alpha-interferon in hepatocellular carcinoma, 136
Styler, Michael. See Brodsky, Jeffrey
Su, Chih-Chung. See Hsu, Wen-Lin
Su, J.Q. See Frytak, S.
See Shaw, E.G.
Sugiura, Seiji. See Ando, Yuichi
Suttora, G. See Leone, B.
Swenerton, K.D. See Woo, H.L.

Tagliaventi, M. See Di Costanzo, F.
Takahashi, T.
—Kato, T.; Kodaira, S.; Koyama, Y.; Sakabe, T.; Tominaga, T.; Hamano, K.; Yasutomi, M.; Ogawa, N.: Prognostic factors of colorectal cancer. Results of multivariate analysis of curative resection cases with or without adjuvant chemotherapy, 408
Takei, Yoshikazu. See Nakano, Hidehiko
Takise, Atsushi. See Nakano, Hidehiko
Taylor, Sarah. See Veldhuizen, Peter J. Van
Tekuzman, Gülten. See Barişta, Ibrahim
Tenllado, Pedro Pablo. See Alba, Emilio
Tentas, K. See Tsavaris, N.B.
Terakawa, Naoki. See Kigawa, Junzo
Terenziani, M. See Zambetti, M.
Tessitore, Judy. See Stuart, Keith
Thierauf, Paul. See Grabenbauer, Gerhard G.
Thuerlimann, B. See Erlichman C.
Ting, Joseph Y. See Abitbol, Andre A.
Tominaga, T. See Takahashi, T.
Tonato, M. See Colozza, M.
See Maranzano, Ernesto
Tood, Mary. See Mani, Sridhar
Torchio, Pierfederico. See Recchia, Francesco
Torkelson, Jane L. See Kennedy, B.J.
Tran, Luu M. See Mark, Rufus J.
Tsavaris, N. See Bafaloukos, D.
Tsavaris, N.B.
—Tentas, K.; Kosmidis, P.; Mylonakis, N.; Sakelaropoulos, N.; Kosmas, C.; Lisaios, B.; Soumilas, A.; Mandrekois, D.; Tsetis, A.; Klonaris, C.: 5-Fluorouracil, epirubicin, and mitomycin C versus 5-fluorouracil, epirubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. A randomized trial, 517
Tsetis, A. See Tsavaris, N.B.
Tsikalakis, D. See Pectasides, D.
Tsuchiya, Satoshi. See Nakano, Hidehiko
Tummarello, Diego. See Giorgi, Francesca
Tyrkus, Michael. See Konski, Andre A.

Uchino, Junichi. See Kondo, Yukifumi
Ueda, Kohji. See Ishii, Eiichi
Unger, Judy. See Lee, Chung K.
Urquiza, Rafael. See Alba, Emilio

Valenza, Roberto. See Gebbia, Vittorio
Valgussa, P. See Zambetti, M.

Vallejo, C.
—Romero, A.; Perez, J.; Cuevas, M.; Lacava, J.; Sabatini, C.; Dominguez, M.; Rodriguez, R.; Barbieri, M.; Romero Acuña, L.; Romero Acuña, J.; Langhi, M.; Amato, S.; Salvadori, M.; Ortiz, E.; Machiavelli, M.; Leone, B.: Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small-cell lung carcinoma, 584
See Leone, B.
Van Belle, S. See Cocquyt, V.
van der Sangen, Maurice J.C. See Levendag, Peter C.
van Putten, Wim L.J. See Levendag, Peter C.
Varma, Datla G.K. See Wright-Browne, Vance
Varthalitis, J. See Pectasides, D.
Vasilev, Steven A. See Moyses, Harry M.
Vaughn, David J.
—Meropol, Neal J.; Armstead, Barbara; Haller, Daniel G.: A pilot trial of 5-FU, leucovorin, and cisplatin with or without adriamycin in advanced cancer, 241
Veldhuizen, Peter J. Van
—Taylor, Sarah: Chylothorax: a complication of a left subclavian vein thrombosis, 99
Veltri, Enzo. See Gridelli, Cesare
Venturoni, Lanfranco. See Recchia, Francesco
Vera, R. See Bellmunt, J.
Vicent, J.M. See Feliu, J.
Vikram, Bhadrasain. See Yu, Lio
Vilches, Y. See Feliu, J.
Vincent, Mark. See Meropol, Neal J.
Voloshin, Michael. See deMagalhaes-Silverman, Margarida
Voutilainen, Leena. See Muhonen, Timo

Wadler, Scott. See Sparano, Joseph A.
Walker, Michael J. See Flaherty, Lawrence E.
Walters, Ronald S. See Anderson, Clay M.
Wang, Chen-Hsu. See Yang, Tsai-Shen
Wang, Hong-Ming. See Yang, Tsai-Shen
Warnick, Ronald E. See Prados, Michael D.
Watanabe, Satoru. See Nakano, Hidehiko
Weaver, Amy L. See Halyard, Michele Y.
Weaving, Ann. See Stein, Moshe E.
Weltman, Eduardo
—Salvajoli, Joao Victor: Letter to the Editor, 431
Weng, Hsiao-Fen. See Lin, Jen-Der
Wheeler, Richard H. See Robert, Francisco
White, Robert M.
—Phase I study of methotrexate administration following 5-fluorouracil, 492
Wibault, Pierre. See Bensmaine, Mohamed-El-Amine
Williamson, Stephen K.
—Wolf, Michael K.; Eisenberger, Mario A.; O'Rourke, Mark A.; Brannon, William; Crawford, E. David: Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group Study, 368
Willis, Brian K. See Ampil, Federico L.
Willson, James K.V. See Meropol, Neal J.
Wilson, J. Frank. See Rock, Douglas B.
Wilson, John. See deMagalhaes-Silverman, Margarida
Witham, M.
—Harnett, P.R.: Adenocarcinoma of the duodenum with liver metastases. Complete remission and long-term survival with 5-fluorouracil chemotherapy —a case report, 305
Wolf, Michael K. See Williamson, Stephen K.
Wolfson, Aaron H. See Abitbol, Andre A.
Woo, H.L.
—Swenerton, K.D.; Hoskins, P.J.: Taxol is active in platinum-resistant endometrial adenocarcinoma, 290
Wright-Browne, Vance
—Kudelka, Andrzej P.; Malpica, Anais; Edwards, Creighton L.; Varma, Datla G.K.; Kavanagh, John J.: Persistent partial molar pregnancy. A report of uterus-preserving treatment and follow-up with magnetic resonance imaging, 534
Wu, Ching-Jung. See Hsu, Wen-Lin

Yang, Tsai-Shen
—Ng, Kim-Thean; Wang, Hong-Ming; Wang, Chen-Hsu; Liaw, Chuang-Chi; Lai, Gi-Ming: Prognostic factors of locoregionally recurrent nasopharyngeal carcinoma—A retrospective review of 182 cases, 337
Yasutomi, M. See Takahashi, T.
Yeilding, Allen
—Bertoli, Luigi; Eisenberg, Peter; Plezia, Patricia; Modiano, Manuel R.; ALberts, David S.; Khojasteh, Ali; Cramer, Michael B.; Hahne, William F.: Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy, 619
Yoo, Nae Chun. See Choi, Jin-Hyuk
Yu, Lio
—Fleckman, Adrienne M.; Chadha, Manjeet; Sacks, Evan; Levetan, Claresa; Vikram, Bhadrasain: Radiation therapy of metastatic pheochromocytoma: case report and review of the literature, 389

Zambetti, M.
—Terenziani, M.; Bartoli, C.; Valagussa, P.; Piotti, P.; Ferranti, C.; Bonadonna, G.: Intermediate doses of cyclophosphamide alone or following adriamycin in advanced breast cancer, 82
Zamora, P. See Feliu, J.
Zempel, Shirley. See Sisson, James C.
Zeppezauer, Michael. See Class, Reiner
Zidan, J.
—Shpendler, M.; Robinson, E.: Treatment of metastatic adrenal cortical carcinoma with etoposide (VP-16) and cisplatin after failure with o,p'DDD. Clinical case reports, 229
Zironi, S. See Di Costanzo, F.

Am J Clin Oncol (CCT) 19(6): 648–654, 1996

© 1996 Lippincott–Raven Publishers, Philadelphia

SUBJECT INDEX

Abdominal lymphoma, Mediterranean, chemotherapy for, 18
Adenomas, pituitary, radiation therapy, 292
Adrenal cortical carcinoma, metastatic, etoposide and cisplatin treatment, 229
Adriamycin
  and cyclophosphamide, for breast cancer, 82
  with 5-fluorouracil, cisplatin, and leucovorin, in advanced cancer, 241
Age factors
  gastric cancer, curative resections, 45
  prognosis in endometrial carcinoma, 595
  toxicity and therapeutic response, in geriatric patients, 371
Aminothiadiazole for mixed mesodermal tumors of uterus, 400
Announcements, 91, 322, 638
Anthracyclines, for Mediterranean abdominal lymphoma, 18
Antibodies
  anti-tyrosinase, malignant melanoma of head and neck, 363
  in melanoma-associated hypopigmentation, 613
  monoclonal, iodine-125-labeled, in human glioma cells, 601
Antigens
  prostate-specific (PSA), divergence of, longitudinal assessment of disease, 217
  prostate-specific (PSA), in radiation therapy of prostate cancer, 65
  tumor-associated, in breast cancer, 459
Apoptosis, histone H1 suppression of leukemia cells, 522

Biologic response modifiers, for metastatic renal cell carcinoma, 149
Bladder carcinoma
  T2-4N0M0, M-CAVI treatment, 344
  transitional cell, tumor-associated antigens, 271
Bleomycin
  carboplatin and vinblastine, with interferon alpha-2A, for malignant melanoma, 296
  and cisplatin, neoadjuvant intraarterial infusion, for cervical cancer,255
  for germ-cell tumors, phase II trial, 487
Bone metastases, palliation with strontium-89, 102
Brachytherapy, high-dose-rate, stage I-B, II-A, and II-B cervical carcinoma, 223
Brain
  liposarcoma metastasis, 351
  metastases, patient acceptability for chemotherapy for metastatic non-small cell lung cancer, 478
  metastases of malignant melanoma, neuroimaging, 49
  metastatic pheochromocytoma, radiation therapy, 389
  tumors, racial factors in prognosis, 114
  whole-brain radiation and phenytoin, Stevens-Johnson syndrome, 32
Breast cancer
  adjuvant chemotherapy, mediastinitis from central vinblastine extravasation, 566
  conservative therapy, at Mayo Clinic, 445
  cyclophosphamide alone or after adriamycin, 82
  decapeptyl (D-TRP-6) phase II trial, 455
  locally advanced and inflammatory, combined therapy with cisplatin,
  doxorubicin, and cyclophosphamide, 10
  in men, adjuvant radiotherapy, 330
  metastases distribution and survival, 569
  metastatic, concurrent infusion of etoposide and cisplatin, 125
  metastatic, filgrastim during mitomycin-C, mitoxantrone, and methotrexate treatment, 232
  phosphotyrosine, Her2-NEU, and epidermal growth factor receptor comparison, 552
  after radiotherapy for lymphomas, lumpectomy and irradiation, 451
  recurrent and metastatic, simultaneous radiochemotherapy, 403
  stage I and II invasive, flow cytometry correlation to clinical factors, hormone receptors, and histopathological grade, 54
  stem cell rescue, etoposide, cyclophosphamide and carboplatin treatment, 169
  tumor-associated antigens, 459
Business plans, physician involvement and assessment of oncology programs, 311

CA 15-3, in breast cancer, 459
CA 19-9, monitoring transitional cell bladder carcinoma, 271
Cancer Management Controversy
  intermediate-risk endometrial cancer, 631
  palliation, 532
Carboplatin
  cisplatin-etoposide, for non-small-cell lung cancer, 245
  cyclophosphamide-etoposide, stem cell rescue in breast cancer, 169
  epirubicin-VP-16 with G-CSF, in small cell lung cancer, 589
  for gliomas, 609
  M-CAVI treatment, for bladder carcinoma, 344
  and radiotherapy, for cervical carcinoma, 317
  and ranimustine, for intraocular retinoblastoma with vitreous seeding, 562
  vinblastine-bleomycin, with interferon alpha-2A, for malignant melanoma, 296
Carcinoembryonic antigen
  in breast cancer, 459
  prognostic factors in colorectal cancer, 408
Catheterization
  chylothorax complication in left subclavian vein thrombosis, 99
  mediastinitis from central vinblastine extravasation, adjuvant chemotherapy in breast cancer, 566
Central nervous system, metastasis of liposarcoma, 351
Cerebellum, metastatic disease, 509
Cervical carcinoma
  advanced squamous cell, phase II trial of didemnin B, 184
  cisplatin and ifosfamide as neoadjuvant chemotherapy, 132
  irradiation and carboplatin, phase I/II study, 317
  locally advanced, bleomycin and cisplatin in neoadjuvant intraarterial infusion, 255
  residual disease in uterus after radiotherapy and hysterectomy, 433
  salvage chemotherapy with mitomycin, vindesine, and cisplatin, 204
  squamous cell, fluorouracil and leucovorin effects, 439
  squamous cell, retinoic acid and neoadjuvant chemotherapy, 442
  stage I-B, II-A, and II-B, high-dose-rate brachytherapy, 223
  stage IIIB, radiotherapy with fluorouracil and cisplatin, 263
Chemodectoma, and metastatic pheochromocytoma, radiation therapy, 389
Chemotherapy
  adjuvant, and curative resection of colorectal cancer, 408
  adjuvant, mediastinitis from central vinblastine extravasation, in breast cancer, 566
  adjuvant, outpatient weekly, for nasopharyngeal carcinoma, 624
  for advanced gynecologic malignancies, 1
  aminothiadiazole, for mixed mesodermal tumors of uterus, 400
  carboplatin, for gliomas, 609
  carboplatin-cisplatin-etoposide, for non-small-cell lung cancer, 245
  carboplatin-epirubicin-VP-16 with G-CSF, in small cell lung cancer, 589
  cisplatin, antiemetic effects of dolasetron, 619
  cisplatin-bleomycin, neoadjuvant intraarterial infusion, for cervical

cancer, 255
cisplatin-doxorubicin- cyclophosphamide (CAP), for stage III breast cancer, 10
cisplatin-fluorouracil and folinic acid, in advanced unresectable head and neck cancer, 140
cisplatin-fluorouracil-leucovorin, in inoperable squamous cell carcinoma of esophagus, 577
cisplatin-ifosfamide, in recurrent/metastatic undifferentiated nasopharyngeal carcinoma, 386
cisplatin-UFT with leucovorin, for advanced non-small-cell lung cancer, 121
cyclophosphamide alone or after adriamycin, in breast cancer, 82
cyclophosphamide-carboplatin-etoposide, stem cell rescue in breast cancer, 169
delayed nausea and emesis, frequency and clinical implications, 199
didemnin B, for advanced squamous cell cervical carcinoma, 184
docetaxel effects, in soft tissue sarcomas, phase II study, 574
epirubicin-ifosfamide-dacarbazine, and G-CSF, for soft tissue sarcomas, 78
estramustine-vinblastine, for metastatic prostate cancer, 581
etoposide-cisplatin, and thoracic radiation therapy salvage, in small-cell carcinoma of lung, 154
etoposide-cisplatin, concurrent infusion in metastatic breast cancer, 125
etoposide-cisplatin, for metastatic adrenal cortical carcinoma, 229
etoposide, in non-small cell lung cancer, 483
fludarabine for previously treated low-grade lymphoma, 268
fluorouracil for duodenal adenocarcinoma with liver metastases, 305
fluorouracil-alpha-interferon, in hepatocellular carcinoma, 136
fluorouracil-epirubicin-mitomycin C with and without leucovorin, in gastric carcinoma, 517
fluorouracil-folinic acid, with or without alpha-2B interferon, in colorectal cancer, 301
fluorouracil-leucovorin, for cervical carcinoma, 439
fluorouracil-leucovorin-cisplatin, with or without adriamycin, in advanced cancer, 241
folinic acid-fluorouracil with or without ifosfamide, in pancreatic cancer, 307
for Hodgkin's disease stage I and II, pediatric, long-term follow-up, 174
ifosfamide, for squamous cell carcinoma of head and neck, 379
ifosfamide/mesna trial, in metastatic prostate cancer, 368
ifosfamide-vinorelbine, for non-small cell lung carcinoma, 584
impact of regulations, tradition, and experimental design on clinical trials, Washington Cancer Trials Conference, 325
interferon alpha and fluorouracil, continuous infusion in pancreatic cancer, 546
interferon alpha with vinblastine and doxorubicin, for renal cell cancer, 384
interferon alpha-2A, with carboplatin, vinblastine, and bleomycin, for advanced malignant melanoma, 296
interferon alpha-2b, with cisplatin and fluorouracil, in head and neck carcinoma, 249
interferon beta, for metastatic renal cell carcinoma, 187
leucovorin-fluorouracil, for metastatic colorectal cancer, 26
leucovorin-fluorouracil, in metastatic prostate cancer, 23
leucovorin-UFT, in advanced gastric carcinoma, 212
for male breast cancer, 330
Mediterranean abdominal lymphoma, 18
merbarone (NSC 336628), for recurrent epithelial ovarian carcinoma, 7
methotrexate after fluorouracil, phase I study, 492
mitomycin-vindesine-cisplatin, for cervical carcinoma, 204
mitoxantrone-cisplatin, in non-small-cell lung cancer, 190
monotherapy, long-term cure of non-small cell lung cancer, 260
neoadjuvant, and retinoic acid, in cervical carcinoma, 442
neoadjuvant, cisplatin-vindesine-fluorouracil and folinic acid, for head and neck cancer, 356
neoadjuvant, ifosfamide-cisplatin for cervical carcinoma, 132
neoadjuvant, M-CAVI treatment, for bladder carcinoma, 344
for olfactory neuroblastoma, 375
oral tamoxifen and intravenous vinblastine, in prostate cancer, 500
patient acceptability, brain metastasis in non-small cell lung cancer, 478
phase II clinical trials, group sequential triangular test, 422
prior to cytoreductive surgery, in testicular carcinoma, 541
prognostic factors for nasopharyngeal carcinoma, 337
ranimustine-carboplatin, for intraocular retinoblastoma with vitreous seeding, 562
and simultaneous radiotherapy, for recurrent metastatic breast carcinoma, 403
tamoxifen addition to dacarbazine and cisplatin, in metastatic malignant melanoma, 108
taxol for endometrial adenocarcinoma, 290
toxicity and therapeutic response, in geriatric patients, 371
vinorelbine-ifosfamide plus MESNA, for non-small-cell lung cancer, 278
VP-16, ifosfamide, cisplatin, vinblastine, and bleomycin, for germ-cell tumors, 487
ZD1694 for gastric cancer, phase II study, 628
Children, Hodgkin's disease stage I and II, long-term follow-up, 174
Chylothorax, complication of left subclavian vein thrombosis, 99
Cisplatin
and bleomycin, neoadjuvant intraarterial infusion, for cervical cancer,255
carboplatin and etoposide, for non-small-cell lung cancer, 245
chemotherapy, antiemetic effects of dolasetron, 619
with doxorubicin and cyclophosphamide (CAP), for stage III breast cancer, 10
and etoposide, concurrent infusion in metastatic breast cancer, 125
and etoposide, for metastatic adrenal cortical carcinoma, 229
and etoposide, thoracic radiation therapy salvage, in small-cell carcinoma of lung, 154
and fluorouracil, outpatient weekly adjuvant chemotherapy, for nasopharyngeal carcinoma, 624
with fluorouracil and radiotherapy, in stage IIIB cervical cancer, 263
fluorouracil-folinic acid, in advanced unresectable head and neck cancer, 140
fluorouracil-leucovorin, in inoperable squamous cell carcinoma of esophagus, 577
fluorouracil-leucovorin, with or without adriamycin, in advanced cancer, 241
for germ-cell tumors, phase II trial, 487
and ifosfamide, neoadjuvant chemotherapy for cervical carcinoma, 132
and ifosfamide, in recurrent/metastatic undifferentiated nasopharyngeal carcinoma, 386
and irradiation for advanced gynecologic malignancies, 1
mitomycin-vindesine, for cervical carcinoma, 204
and mitoxantrone, in non-small-cell lung cancer, 190
and tamoxifen, in metastatic malignant melanoma, 108
and thoracic radiotherapy, for small-cell lung cancer, 193
and UFT with leucovorin, for advanced non-small-cell lung cancer, 121
vindesine-fluorouracil, and folinic acid, for head and neck cancer, 356
Clinical Case Report
Persistent Partial Molar Pregnancy. Uterus-preserving Treatment and Follow-up with MRI, 534
Clinical trials
impact of regulations, tradition, and experimental design, Washington Cancer Trials Conference, 325
phase II, group sequential triangular test, 422
Colorectal cancer
fluorouracil and folinic acid, with or without alpha-2B interferon, 301
metastatic, fluorouracil and leucovorin therapy, 26
skin tests, serum immunosuppressive factor and cytokines of peripheral mononuclear cells, 159

Computed tomography (CT), cerebral spread of malignant melanoma, 49
Cyclophosphamide
alone or after adriamycin, in breast cancer, 82
carboplatin and etoposide, stem cell rescue in breast cancer, 169
with cisplatin and doxorubicin (CAP), for stage III breast cancer, 10
Cytokines of peripheral mononuclear cells, skin tests in colorectal cancer, 159
Cytoreductive surgery, chemotherapy prior to, in testicular carcinoma, 541

Dacarbazine
with epirubicin and ifosfamide, accelerated, for soft tissue sarcomas, 78
and tamoxifen, in metastatic malignant melanoma, 108
Decapeptyl (D-TRP-6) in breast cancer, phase II trial, 455
Dermatomyositis, and nasopharyngeal carcinoma, 35
Diagnostic factors, PSA divergence, in prostate cancer, 217
Didemnin B (NSC #335319), phase II trial, for advanced squamous cell carcinoma of cervix, 184
DNA flow cytometry
correlation with surgical staging and hormone receptors in endometrial adenocarcinoma, 164
in stage I and II invasive breast carcinoma, 54
Docetaxel
in soft tissue sarcomas, phase II study, 574
Dolasetron, antiemetic effects, in cisplatin chemotherapy, 619
Doxorubicin with cisplatin and cyclophosphamide (CAP), for stage III breast cancer, 10
for olfactory neuroblastoma, 375
and vinblastine, with interferon alpha, for renal cell carcioma, 384
Duodenal adenocarcinoma with liver metastases, 305

Editorial, 636
Emesis
delayed, frequency and clinical implications, 199
dolasetron effects, in cisplatin chemotherapy, 619
Endometrial carcinoma
age and race as prognostic factors, 595
DNA flow cytometry correlation with surgical staging and hormone receptors, 164
intermediate-risk, management approach, 631
platinum-resistant, taxol activity, 290
Epidermal growth factor receptor
in glioma cells, iodine-125-labeled monoclonal antibodies, 601
phosphotyrosine and Her2-NEU, comparison in breast cancer, 552
Epirubicin
carboplatin-VP-16 with G-CSF, in small cell lung cancer, 589
fluorouracil-mitomycin C with and without leucovorin, in gastric carcinoma, 517
ifosfamide-dacarbazine (EID), and G-CSF, for soft tissue sarcomas, 78
Episcleral plaque thermoradiotherapy of posterior uveal melanomas, 207
Erratum, 637
Esophagus carcinoma, squamous cell, inoperable, cisplatin-fluorouracil-leucovorin, 577
Estramustine and vinblastine, for metastatic prostate cancer, 581
Estrogen receptors
and DNA flow cytometry, in endometrial adenocarcinoma, 164
metastases distribution and survival in breast cancer, 569
Etoposide
carboplatin and cisplatin, for non-small-cell lung cancer, 245
and cisplatin, concurrent infusion in metastatic breast cancer, 125
and cisplatin, for metastatic adrenal cortical carcinoma, 229
and cisplatin, thoracic radiation therapy salvage, in small-cell carcinoma of lung, 154
cyclophosphamide and carboplatin, stem cell rescue in breast cancer, 169
in non-small cell lung cancer, 483
alpha-Fetoprotein, in gallbladder carcinoma, 465

Filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate treatment for breast cancer, 232
Flow cytometry
in breast cancer, correlation to clinical factors, hormone receptors, and histopathological grade, 54
in endometrial adenocarcinoma, correlation with surgical staging and hormone receptors, 164
Fludarabine for low-grade lymphoma, 268
5-Fluorouracil and alpha-interferon in hepatocellular carcinoma, 136
and cisplatin, outpatient weekly adjuvant chemotherapy, for nasopharyngeal carcinoma, 624
cisplatin and folinic acid, in advanced unresectable head and neck cancer, 140
cisplatin-leucovorin, in inoperable squamous cell carcinoma of esophagus, 577
with cisplatin and radiotherapy, in stage IIIB cervical cancer, 263
duodenal adenocarcinoma with liver metastases, 305
epirubicin-mitomycin C with and without leucovorin, in gastric carcinoma, 517
and folinic acid, with or without alpha-2B interferon, in colorectal cancer, 301
and folinic acid with or without ifosfamide, for pancreatic cancer, 307
high-dose, and leucovorin, in metastatic prostate cancer, 23
and interferon-alpha, continuous infusion in pancreatic cancer, 546
and irradiation for advanced gynecologic malignancies, 1 and leucovorin, for cervical carcinoma, 439
and leucovorin, for metastatic colorectal cancer, 26
leucovorin and cisplatin, with or without adriamycin, in advanced cancer, 241
methotrexate after administration of, phase I study, 492
vindesine-cisplatin, and folinic acid, for head and neck cancer, 356
Folinic acid
cisplatin and fluorouracil, in advanced unresectable head and neck cancer, 140
and cisplatin-vindesine-fluorouracil, for head and neck cancer, 356
and fluorouracil, with or without alpha-2B interferon, in colorectal cancer, 301
and fluorouracil with or without ifosfamide, for pancreatic cancer, 307

Gallbladder carcinoma, alpha-fetoprotein levels, 465
Gastric cancer
advanced, leucovorin and UFT treatment, 212
fluorouracil-epirubicin-mitomycin C, with and without leucovorin, 517
in young patients, curative resections, 45
ZD1694 treatment, phase II study, 628
Gastrointestinal tract cancer, upper, 5-fluorouracil, leucovorin and cisplatin, with or without adriamycin, 241
Germ-cell tumors, VP-16, ifosfamide, cisplatin, vinblastine, and bleomycin trial, 487
Gliomas
carboplatin effects, 609
iodine-125-labeled monoclonal antibodies, in vitro evaluation, 601
Granulocyte-colony stimulating factor (G-CSF)
carboplatin-epirubicin-VP-16, in small cell lung cancer, 589
and epirubicin-ifosfamide-dacarbazine (EID), and G-CSF, for soft tissue sarcomas, 78
filgrastim, during mitomycin-C, mitoxantrone, and methotrexate treatment for breast cancer, 232
Group sequential triangular test for phase II clinical trials, 422
Growth suppression in leukemia cells, by histone H1, 522
Gynecologic tract
See also Cervical carcinoma.
advanced carcinoma, irradiation and chemotherapy, 1
postirradiation sarcoma, 59
uterine mixed mesodermal tumors, aminothiadiazole trial, 400

Head and neck cancer
advanced unresectable, cisplatin, fluorouracil, and folinic acid, 140
local tumor control in radiation therapy, 469

malignant melanoma, 363
methotrexate after fluorouracil, phase I study, 492
neoadjuvant chemotherapy with cisplatin-vindesine-fluorouracil and folinic acid, 356
recurrent and/or metastatic, interferon alpha-2b with cisplatin and fluorouracil, 249
squamous cell, ifosfamide study, 379
Healthcare, physician involvement and assessment of oncology programs, 311
Hepatocellular carcinoma, fluorouracil and alpha-interferon, 136
Her2-NEU, phosphotyrosine, and epidermal growth factor receptor, comparison in breast cancer, 552
Histone H1 suppression of tumor growth of leukemia cells in vitro, ex vivo, and animal model, 522
Histopathology, correlation with flow cytometry in stage I and II invasive breast carcinoma, 54
Hodgkin's disease
early-stage, therapeutic radiology, 235
stage I and II, pediatric, long-term follow-up, 174
Hormonal therapy for male breast cancer, 330
Hormone receptors
decapeptyl (D-TRP-6) for breast cancer, 455
DNA flow cytometry in endometrial adenocarcinoma, 164
Hyperthermia, episcleral plaque radiotherapy, of posterior uveal melanomas, 207
Hypopigmentation, melanoma-associated, antibody evaluation, 613
Hysterectomy, and radiotherapy for cervical carcinoma, residual disease in uterus, 433

Ifosfamide
and cisplatin, neoadjuvant chemotherapy for cervical carcinoma, 132
and cisplatin, in recurrent/metastatic undifferentiated nasopharyngeal carcinoma, 386
with epirubicin and dacarbazine, accelerated, for soft tissue sarcomas, 78
with fluorouracil and folinic acid, for pancreatic cancer, 307
for germ-cell tumors, phase II trial, 487
and mesna, for metastatic prostate cancer, 368
for squamous cell carcinoma of head and neck, 379
and vinorelbine, for non-small cell lung carcinoma, 584
and vinorelbine plus MESNA, for non-small-cell lung cancer, 278
Immuneron, gamma-interferon, for metastatic renal cell carcinoma, 149
Immunohistochemistry, alpha-fetoprotein levels in gallbladder carcinoma, 465
Immunosuppressive factor, skin tests in colorectal cancer, 159
Interferon
alpha, and fluorouracil, continuous infusion in pancreatic cancer, 546
alpha, and fluorouracil, in hepatocellular carcinoma, 136
alpha, with vinblastine and doxorubicin, for renal cell cancer, 384
alpha-2A, with carboplatin, vinblastine, and bleomycin, for advanced malignant melanoma, 296
alpha-2B, with cisplatin and fluorouracil, in head and neck carcinoma, 249
alpha-2B, with fluorouracil and folinic acid, in colorectal cancer, 301
beta, for metastatic renal cell carcinoma, 187
gamma, for metastatic renal cell carcinoma, 149
Iodine-125, monoclonal antibody (MAb 425), in vitro evaluation in human glioma cells, 601

Kaposi's sarcoma on lymphedematous arm after mastectomy, 87

Letters to the Editor
neuroendocrine primary small cell carcinoma of breast, 322; author's reply, 322
Stevens-Johnson syndrome, 431
Leucovorin
cisplatin-fluorouracil, in inoperable squamous cell carcinoma of esophagus, 577
cisplatin-UFT, for advanced non-small-cell lung cancer, 121
and fluorouracil, for cervical carcinoma, 439
and fluorouracil, for metastatic colorectal cancer, 26
and fluorouracil, in metastatic prostate cancer, 23
fluorouracil-cisplatin, with or without adriamycin, in advanced cancer, 241
and fluorouracil-epirubicin-mitomycin C, in gastric carcinoma, 517
and UFT, in advanced gastric carcinoma, 212
Leukemia, growth suppression of tumor cells in vitro, ex vivo, and animal model, by histone H1, 522
Linear analogue scale, quality of life in cancer, 394
Liposarcoma, CNS metastasis, 351
Liver metastasis, in duodenum adenocarcinoma, 305
Lumpectomy. breast cancer after radiation for lymphomas, 451
Lung cancer
M_0 carcinoma, radiotherapy effects, 512
non-small cell, carboplatin-cisplatin-etoposide treatment, 245
non-small cell, cisplatin-mitroxantrone, 190
non-small cell, cisplatin-UFT with leucovorin, 121
non-small cell, etoposide infusion, 483
non-small cell, ifosfamide-vinorelbine, 584
non-small cell, long-term cure with monotherapy, 260
non-small cell, PET of radiotherapy treatment, 416
non-small cell, stage III-IV, vinorelbine and ifosfamide plus MESNA, 278
non-small cell, with brain metastasis, patient acceptability for chemotherapy, 478
small cell, carboplatin-epirubicin-VP-16 with G-CSF, 589
small cell, cisplatin chemotherapy and hyperfractionated thoracic radiotherapy, 193
small cell, cisplatin/etoposide and thoracic radiotherapy, 154
Luteinizing hormone-releasing hormone analogue, decapeptyl (D-TRP-6) for breast cancer, 455
Lymphedema after mastectomy, Kaposi's sarcoma on arm, 87
Lymphomas
abdominal, Mediterranean, chemotherapy for, 18
Hodgkin's disease, breast cancer treatment after radiotherapy for, 451
Hodgkin's early-stage, therapeutic radiology, 235
non-Hodgkin's, low-grade, fludarabine treatment, 268
non-Hodgkin's, radiotherapy with long-term follow-up, 93
non-Hodgkin's, splenectomy effectiveness, 558

Magnetic resonance imaging (MRI), persistent partial molar pregnancy, 534
Mastectomy, and Kaposi's sarcoma on lymphedematous arm, 87
M-CAVI for bladder carcinoma, 344
Mediastinitis from central vinblastine extravasation, adjuvant chemotherapy in breast cancer, 566
Mediastinum in lung carcinoma M_0, 512
Mediterranean abdominal lymphoma, 18
Medulloblastoma, postoperative radiotherapy, 73
Melanomas
advanced malignant, interferon alpha-2A, with carboplatin, vinblastine, and bleomycin, 296
hypopigmentation, antibody evaluation, 613
intraocular, microwave thermoradiotherapy, 281
malignant, CT of cerebral spread, 49
malignant, of head and neck, 363
metastatic malignant, tamoxifen addition to dacarbazine and cisplatin, 108
uveal, posterior, episcleral plaque thermoradiotherapy, 207
Merbarone (NSC 336628) for epithelial ovarian carcinoma, 7
Metaiodobenzylguanidine (MIBG), 125-I, for neuroblastoma, 144
Metastases
brain, patient acceptability for chemotherapy for metastatic non-small cell lung cancer, 478
in cerebellum, 509
distribution, and survival in breast cancer, 569
in occult thyroid carcinoma, comparison with nonoccult, 504
Metastron, strontium-89 chloride, palliation of bony metastases, 102

Methotrexate
after fluorouracil, phase I study, 492
and doxorubicin, for olfactory neuroblastoma, 375
mitomycin-C and mitoxantrone, for metastatic breast cancer, prophylactic
filgrastim, 232
Microwave hyperthermia, for intraocular melanoma, 281
Mitomycin, vindesine, and cisplatin, for cervical carcinoma, 204
Mitomycin C
fluorouracil-epirubicin with and without leucovorin, in gastric carcinoma, 517
mitoxantrone and methotrexate, for metastatic breast cancer, prophylactic filgrastim, 232
Mitotane failure in metastatic adrenal cortical carcinoma, etoposide and cisplatin treatment, 229
Mitoxantrone
and cisplatin, in non-small-cell lung cancer, 190
mitomycin-C and methotrexate, for metastatic breast cancer, prophylactic filgrastim, 232
Mononuclear cells, peripheral, cytokine production, skin tests in colorectal cancer, 159
Multivariate analysis, prognostic factors in colorectal cancer, 408

Nasopharyngeal carcinoma
with dermatomyositis, 35
outpatient weekly adjuvant chemotherapy, 624
prognostic factors, 337
recurrent/metastatic undifferentiated, cisplatin/ifosfamide study, 386
Nausea, delayed, frequency and clinical implications, 199
Neck cancer. *See* Head and neck cancer.
Nerve compression syndrome, metastatic pheochromocytoma, radiation therapy, 389
Neuroblastoma
125-I MIBG treatment, 144
olfactory, treatment modalities, 375
Neuroimaging, cerebral spread of malignant melanoma, 49
Neutrophilic dermatosis with osteosarcoma, 349
Non-Hodgkin's lymphoma. *See* Lymphomas.
NSC 336628, merbarone for recurrent epithelial ovarian carcinoma, 7
NSC #335319. *See* Didemnin B

Olfactory neuroblastoma, treatment modalities, 375
Oncology programs, physician involvement and assessment of, 311
Osteosarcoma with Sweet syndrome, 349
Ovarian carcinoma, epithelial, recurrent, merbarone (NSC 336628) therapy, 7

Palliation
management controversy, 532
simultaneous radiochemotherapy, for recurrent metastatic breast carcinoma, 403
strontium-89 chloride, for bony metastases, 102
Pancreatic cancer
folinic acid and fluorouracil with or without ifosfamide, 307
interferon-alpha and fluorouracil, phase II trial of continuous infusion, 546
Phenytoin, and whole-brain radiation, Stevens-Johnson syndrome, 32
Pheochromocytoma, metastatic, radiation therapy, 389
Phosphotyrosine, Her2-NEU, and epidermal growth factor receptor, comparison in breast cancer, 552
Physician involvement and assessment of hospital oncology programs, 311
Pituitary adenoma, radiation therapy, 292
Platinum resistance, endometrial adenocarcinoma, taxol activity, 290
Positron emission tomography (PET), non-small-cell lung cancer, radiotherapy treatment, 416
Prednisone for nasopharyngeal carcinoma with dermatomyositis, 35
Pregnancy, persistent partial molar, uterus-preserving treatment and follow-up with MRI, 534
Progesterone receptors, and DNA flow cytometry, in endometrial adenocarcinoma, 164
Prognostic factors
age and race, in endometrial carcinoma, 595
colorectal cancer, curative resection with or without adjuvant chemotherapy, 408
flow cytometry in breast carcinoma, 54
nasopharyngeal carcinoma, 337
PSA levels in radiation therapy of prostate cancer, 65
race, in brain tumors, 114
Prostate cancer
hormone-refractory, oral tamoxifen and intravenous vinblastine, 500
metastatic, ifosfamide/mesna trial, 368
metastatic, leucovorin and high-dose fluorouracil, 23
metastatic, vinblastine and estramustine, 581
PSA divergence, 217
PSA levels in radiation therapy, 65

Quality control, postoperative radiotherapy for medulloblastoma, 73
Quality of life
in cancer, visual-analogue and categorical models, 394
simultaneous radiochemotherapy, for recurrent metastatic breast carcinoma, 403
Questionnaires, quality of life in cancer, visual-analogue and categorical models, 394

Racial factors
prognosis in endometrial carcinoma, 595
prognosis of brain tumors, 114
Radiation
for advanced gynecologic malignancies, 1
gynecologic sarcoma induced by, 59
high-dose-rate brachytherapy, stage I-B, II-A, and II-B cervical carcinoma, 223
whole-brain, and phenytoin, Stevens-Johnson syndrome, 32
Radiotherapy
adjuvant, for male breast cancer, 330
breast cancer, conservative treatment at Mayo Clinic, 445
and carboplatin, for cervical carcinoma, 317
cerebellar metastatic disease, 509
for cervical carcinoma, residual disease in uterus, 433
for early-stage Hodgkin's lymphoma, 235
with fluorouracil and cisplatin, in stage IIIB cervical cancer, 263
Hodgkin's disease stage I and II, pediatric, long-term follow-up, 174
hyperfractionated thoracic, and cisplatin, for small-cell lung cancer, 193
local tumor control of head and neck cancers, 469
in lung carcinoma M_0, 512
for lymphomas, lumpectomy and irradiation for breast cancer, 451
for metastatic pheochromocytoma, 389
microwave thermal, for intraocular melanoma, 281
nasopharyngeal carcinoma with dermatomyositis, 35
non-Hodgkin's lymphoma, long-term follow-up, 93
non-small-cell lung cancer, PET evaluation, 416
for olfactory neuroblastoma, 375
for pituitary adenomas, 292
postoperative, of medulloblastoma, 73
of prostate cancer, prognostic value of PSA levels, 65
and simultaneous chemotherapy, for recurrent metastatic breast carcinoma, 403
without steroids, in metastatic spinal cord compression, 179
thermal, episcleral plaque, for posterior uveal melanomas, 207
thoracic, and cisplatin/etoposide, in small-cell carcinoma of lung, 154
for vaginal carcinoma, 39
Ranimustine and carboplatin, for intraocular retinoblastoma with vitreous seeding, 562
Receptors
hormone, and DNA flow cytometry, in endometrial adenocarcinoma, 164
steroid, correlation with flow cytometry in stage I and II invasive breast carcinoma, 54

Renal cell carcinoma
doxorubicin and vinblastine, with interferon alpha, 384
metastatic, gamma-interferon effects, 149
metastatic, beta-interferon effects, 187
Resections, curative
colorectal cancer, with or without adjuvant chemotherapy, 408
gastric cancer in young patients, 45
Retinoblastoma, intraocular, with vitreous seeding, carboplatin and ranimustine, 562
13-*cis*-Retinoic acid
and neoadjuvant chemotherapy, in cervical carcinoma, 442

Sarcomas
Kaposi's, on lymphedematous arm after mastectomy, 87
lipo-, CNS metastasis, 351
osteo-, with Sweet syndrome, 349
postirradiation, of gynecologic tract, 59
soft tissue, docetaxel effects, phase II study, 574
soft tissue, EID and G-CSF regimen, 78
Signal transduction, phosphotyrosine, Her2-NEU, and epidermal growth factor receptor, comparison in breast cancer, 552
Skin tests in colorectal cancer, serum immunosuppressive factor and cytokines of peripheral mononuclear cells, 159
Soft tissue sarcomas, docetaxel effects, phase II study, 574
Spinal cord metastatic compression, radiotherapy without steroids, 179
Splenectomy for non-Hodgkin's lymphoma, 558
Steroids
lack of, radiotherapy in metastatic spinal cord compression, 179
receptors, correlation with flow cytometry in stage I and II invasive breast carcinoma, 54
Stevens-Johnson syndrome from whole-brain radiation and phenytoin, 32
Strontium-89 palliation of bony metastases, 102
Subclavian vein thrombosis, chylothorax development, 99
Sun exposure, malignant melanoma of head and neck, 363
Survival rates
breast cancer, conservative treatment at Mayo Clinic, 445
cerebellar metastatic disease, 509
chemotherapy and irradiation for advanced gynecologic malignancies, 1
combined therapy with cisplatin, doxorubicin, and cyclophosphamide, for stage III breast cancer, 10
gastric cancer, curative resections in young patients, 45
gliomas, carboplatin treatment, 609
high-dose-rate brachytherapy, stage I-B, II-A, and II-B cervical carcinoma, 223
male breast cancer, 330
metastases distribution, in breast cancer, 569
metastatic breast cancer, concurrent infusion of etoposide and cisplatin, 125
metastatic renal cell carcinoma, gamma-interferon treatment, 149
nasopharyngeal carcinoma with dermatomyositis, 35
neuroblastoma, 125-I MIBG treatment, 144
non-Hodgkin's lymphoma, radiotherapy with long-term follow-up, 93
non-small-cell lung cancer, long-term cure with monotherapy, 260
occult thyroid carcinoma, comparison with nonoccult, 504
postirradiation sarcoma of gynecologic tract, 59
postoperative radiotherapy for medulloblastoma, 73
prognostic factors in colorectal cancer, 408
race in prognosis of brain tumors, 114
radiation therapy for vaginal carcinoma, 39
radiotherapy for early-stage Hodgkin's lymphoma, 235
small-cell lung carcinoma, cisplatin/etoposide and thoracic radiotherapy, 154
Sweet syndrome with osteosarcoma, 349

Tamoxifen
addition to dacarbazine and cisplatin, in metastatic malignant melanoma, 108
oral, and intravenous vinblastine, in prostate cancer, 500
Taxol, in platinum-resistant endometrial adenocarcinoma, 290
Testicular carcinoma, chemotherapy prior to cytoreductive surgery, 541
Thrombosis, subclavian vein, chylothorax development, 99
Thyroid carcinoma, occult, comparison with nonoccult, 504
Toxicity
chemotherapy and irradiation for advanced gynecologic malignancies, 1
chemotherapy for elderly patients, 371
cisplatin-fluorouracil-leucovorin, in esophageal carcioma, 577
combined therapy with cisplatin, doxorubicin, and cyclophosphamide, for stage III breast cancer, 10
cyclophosphamide and adriamycin, for breast cancer, 82
didemnin B, for advanced squamous cell cervical carcinoma, 184
doxorubicin and vinblastine, with interferon alpha, for renal cell carcinoma, 384
etoposide, cyclophosphamide and carboplatin, stem cell rescue in breast cancer, 169
etoposide infusion, in non-small cell lung cancer, 483
fluorouracil and alpha-interferon, in hepatocellular carcinoma, 136
fluorouracil and leucovorin, in metastatic colorectal cancer, 26
gamma-interferon, for metastatic renal cell carcinoma, 149
hyperfractionated thoracic radiotherapy, and cisplatin, for small-cell lung cancer, 193
ifosfamide/mesna, for metastatic prostate cancer, 368
beta-interferon, for metastatic renal cell carcinoma, 187
leucovorin and high-dose fluorouracil, in metastatic prostate cancer, 23
merbarone (NSC 336628) therapy for recurrent epithelial ovarian carcinoma, 7
simultaneous radiochemotherapy, for recurrent metastatic breast carcinoma, 403
Treatment times, local tumor control in radiation therapy, in head and neck cancer, 469
Triangular test, group sequential, for phase II clinical trials, 422
Tumor polypeptide antigen, in breast cancer, 459
Tumor registry, and data management, physician involvement and assessment of oncology programs, 311
Tumor-associated trypsin inhibitor (TATI), monitoring transitional cell bladder carcinoma, 271
Tyrosinase antibodies, in melanoma-associated hypopigmentation, 613

UFT
and cisplatin with leucovorin, for advanced non-small-cell lung cancer, 121
and leucovorin, in advanced gastric carcinoma, 212
Uterus
endometrial carcinoma. *See* Endometrial carcinoma.
mixed mesodermal tumors, aminothiadiazole trial, 400
persistent partial molar pregnancy, follow-up with MRI, 534
residual disease after radiotherapy and hysterectomy in cervical carcinoma, 433
Uveal melanomas
microwave thermoradiotherapy, 281
posterior, episcleral plaque thermoradiotherapy, 207

Vaginal carcinoma, primary, radiation therapy, 39
Vinblastine
carboplatin and bleomycin, with interferon alpha-2A, for malignant melanoma, 296
and doxorubicin, with interferon alpha, for renal cell carcioma, 384
and estramustine, for metastatic prostate cancer, 581
for germ-cell tumors, phase II trial, 487
intravenous, and oral tamoxifen, in prostate cancer, 500
mediastinitis from central extravasation, adjuvant chemotherapy in breast cancer, 566
Vindesine
cisplatin-fluorouracil, and folinic acid, for head and neck cancer, 356
mitomycin and cisplatin, for cervical carcinoma, 204

Vinorelbine
and ifosfamide, for non-small cell lung carcinoma, 584
and ifosfamide plus MESNA, for non-small-cell lung cancer, 278
for non-small-cell lung cancer, long-term cure with monotherapy, 260
Vitreous seeding in intraocular retinoblastoma, carboplatin and ranimustine, 562

VP-16
carboplatin-epirubicin with G-CSF, in small cell lung cancer, 589
for germ-cell tumors, phase II trial, 487

Washington Cancer Trials Conference, impact of regulations, tradition, and experimental design on clinical trials, 325

ZD1694, in gastric cancer, phase II study, 628

UNITED STATES POSTAL SERVICE

Statement of Ownership, Management, and Circulat
(Required by 39 USC

1. Publication Title	2. Publication Number	3. Filing Date
American Journal of Clinical Oncology: Cancer Clinical Trials	0 2 7 7 - 3 7 3 2	October 1, 1996
4. Issue Frequency: Bimonthly	5. Number of Issues Published Annually: 6	6. Annual Subscription Price: $164.00 US

7. Complete Mailing Address of Known Office of Publication (Not printer) (Street, city, county, state, and ZIP+4): Lippincott-Raven Publishers, 12107 Insurance Way, Hagerstown, MD 21740 — Contact Person / Telephone

8. Complete Mailing Address of Headquarters or General Business Office of Publisher (Not printer): 227 East Washington Square, Philadelphia, PA 19106

9. Full Names and Complete Mailing Addresses of Publisher, Editor, and Managing Editor (Do not leave blank)

Publisher (Name and complete mailing address): Lippincott-Raven Publishers, 227 East Washington Square, Philadelphia, PA 19106

Editor (Name and complete mailing address): Dr. Luther W. Brady, Dept. of Radiation Oncology and Nuclear Medicine, Hahnemann Universi..., Broad & Vine Streets, MS 2000, Philadelphia, PA 19102

Managing Editor (Name and complete mailing address): Greg Fagan, Lippincott-Raven Publishers, 1185 Ave of the Americas, N.Y., N.Y. 10036

10. Owner (Do not leave blank. If the publication is owned by a corporation, give the name and address of the corporation immediately followed by the names and addresses of all stockholders owning or holding 1 percent or more of the total amount of stock. If not owned by a corporation, give the names and addresses of the individual owners. If owned by a partnership or other unincorporated firm, give its name and address as well as those of each individual owner. If the publication is published by a nonprofit organization, give its name and address.)

Full Name	Complete Mailing Address
Lippincott-Raven Publishers	227 East Washington Square, Phila., PA 19106
Wolters Kluwer US	1185 Avenue of the Americas, N.Y., N.Y. 10036
Wolters Kluwer nv (owns 100% of stock)	Stadouderskade 1
	1054 ES Amsterdam, The Netherlands

11. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages, or Other Securities. If none, check box → ☐ None

Full Name	Complete Mailing Address
None	

12. Tax Status (For completion by nonprofit organizations authorized to mail at special rates) (Check one)
The purpose, function, and nonprofit status of this organization and the exempt status for federal income tax purposes:
☐ Has Not Changed During Preceding 12 Months
☐ Has Changed During Preceding 12 Months (Publisher must submit explanation of change with this statement)

PS Form 3526, September 1995 (See instructions on Reverse)

13. Publication Title: American Journal of Clinical Oncology: Cancer Clinical Trials	14. Issue Date for Circulation Data Below: Vol., 19 #5	
15. Extent and Nature of Circulation	Average No. Copies Each Issue During Preceding 12 Months	Actual No. Copies of Single Issue Published Nearest to Filing Date
a. Total Number of Copies (Net press run)	2,346	2,100
b. Paid and/or Requested Circulation — (1) Sales Through Dealers and Carriers, Street Vendors, and Counter Sales (Not Mailed)	—	—
b. Paid and/or Requested Circulation — (2) Paid or Requested Mail Subscriptions (Include advertiser's proof copies and exchange copies)	1,275	1,268
c. Total Paid and/or Requested Circulation (Sum of 15b(1) and 15b(2))	1,275	1,268
d. Free Distribution by Mail (Samples, complimentary, and other free)	220	267
e. Free Distribution Outside the Mail (Carriers or other means)	—	—
f. Total Free Distribution (Sum of 15d and 15e)	220	267
g. Total Distribution (Sum of 15c and 15f)	1,495	1,535
h. Copies not Distributed — (1) Office Use, Leftovers, Spoiled	851	565
h. Copies not Distributed — (2) Returns from News Agents	—	—
i. Total (Sum of 15g, 15h(1), and 15h(2))	2,346	2,100
Percent Paid and/or Requested Circulation (15c / 15g x 100)	85%	82%

16. Publication of Statement of Ownership
☐ Publication required. Will be printed in the Vol. 19, #6 issue of this publication.
☐ Publication not required.

17. Signature and Title of Editor, Publisher, Business Manager, or Owner: Beverly V. Dietrich (Circulation Director) — Date: 9/26/96

I certify that all information furnished on this form is true and complete. I understand that anyone who furnishes false or misleading information on this form or who omits material or information requested on the form may be subject to criminal sanctions (including fines and imprisonment) and/or civil sanctions (including multiple damages and civil penalties).

Instructions to Publishers

1. Complete and file one copy of this form with your postmaster annually on or before October 1. Keep a copy of the completed form for your records.
2. In cases where the stockholder or security holder is a trustee, include in items 10 and 11 the name of the person or corporation for whom the trustee is acting. Also include the names and addresses of individuals who are stockholders who own or hold 1 percent or more of the total amount of bonds, mortgages, or other securities of the publishing corporation. In item 11, if none, check the box. Use blank sheets if more space is required.
3. Be sure to furnish all circulation information called for in item 15. Free circulation must be shown in items 15d, e, and f.
4. If the publication had second-class authorization as a general or requester publication, this Statement of Ownership, Management, and Circulation must be published; it must be printed in any issue in October or, if the publication is not published during October, the first issue printed after October.
5. In item 16, indicate the date of the issue in which this Statement of Ownership will be published.
6. Item 17 must be signed.

Failure to file or publish a statement of ownership may lead to suspension of second-class authorization.

PS Form 3526, September 1995 (Reverse)